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ABSTRACT
STUDY OF ANTI-PROLIFERATIVE ACTIVITY OF INSPIRED ESTRONE
ANALOGS ON HEPATOCELLULAR CARCINOMA
SARA ELGAZWI
2018
Hepatocellular carcinoma (HCC) is considered the third leading cause of death
from cancer. Overall survival rate is significantly low, due to the emerging resistance
to chemotherapeutic agents and lack of selectivity. Recent studies have demonstrated
that epidermal growth factor receptor (EGFR) is a promising molecular target for
cancer therapy, especially HCC. Current studies showed that cucurbitacins are potent
anticancer compounds which target EGFR. This prompted us to investigate the antiproliferative activity of novel cucurbitacins inspired estrone analogs (CIEA) against
sensitive and resistant HepG2 cell lines. Anti-proliferation activity of 20 CIEA analogs
were examined against HepG2 using MTT assay and showed that antiproliferative
activity of analogs MMA132, and MMA102 IC50 are 2μM, and 3 μM respectively in
comparison to Erlotinib 25 μM. Study of the mechanism of anti-proliferation effects of
these novel analogs was elucidated. Western blot analysis showed that MMA132, and
MMA102 significantly inhibit EGFR/pEGFR, RAF/pRAF, MEK/pMEK, and
ERK/PERK. Cell cycle analysis on HepG2 cell line revealed that MMA132 and
MMA102 arrested the cells at G1 phase and inhibited the HepG2 cell migration after
24 hr. MMA132 induced apoptosis through activation of caspase 3,9 and inhibition of
PARP.
Treatment of HepG2-R (Erlotinib resistant) with MMA132 and MMA102 showed
that these two novel drug candidates still possessing potent anti-proliferation activities
against HepG2-R. Further characterization of the anti-proliferation of these lead
compounds was demonstrated through mapping the change in EGFR signaling pathway
(ERK, pERK, RAS, AKT and MEK) by western blot, cell cycle analysis, demonstrated
that MMA132 and MMA102 stop the cell cycle of HepG2-R at G2 phase and inhibited
cell migration after 48hrs. HepG2-R cell line significantly expressed MRP2 in
comparing to sensitive cells. Moreover, MK571(MRP2 inhibitor) showed an inhibitory

xiii
effect on resistant HepG2-R cancer cell lines. Combination of MMA132 with MK571
(13 µM and 15 µM respectively) showed a significant increase in the cytotoxicity of
MK571 from 18.5 µM to 10 µM. In conclusion, our study documented the discovery
of novel estrone analogs as potential drug candidates for treatment of HCC and
promising chemotherapeutic agent toward HepG2 resistant to erlotinib.
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Chapter One
1. General Introduction and Background
1.1 Hepatocellular Carcinoma
Hepatocellular carcinoma is the sixth most common cancers with about 500,000
people diagnosed each year, and it’s reported as a third largest cause of cancer –related
death1,2. The treatment is challenging, 5-years survival rate is estimated to be less than
5%3.The most common causes of death among HCC patients are recurrence,
metastasis, and the development of new primary tumors4.
1.2 Causes for Hepatocellular carcinoma
Many risk factors are responsible and play role in HCC progress. Induced
Hepatitis C, B virus (HCV, HBV) infection are associated with the highest HCC incidence
in persons with cirrhosis, the data about HCC risk is still limited but factors like older age,
male sex, the severity of compensated cirrhosis, and sustained activity of liver disease are
important predictors of HCC. More studies are needed to demonstrated the mechanism of
factors such as HBV genotype/mutant, occult HBV, HIV confection and other risk factors
that cause HCC (e.g., obesity, diabetes)5. (Figure 1.1)
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Figure 1.1 Causes of Hepatocellular carcinoma (HCC).

1.2.1 Virus induced hepatocarcinogenetic
Approximately 2 billion and 170 million people around the world infected by
hepatitis B virus (HBV) and hepatitis C virus (HCV). There are many different mechanisms
to promote HCC by HBV and HCV, by target and binding to growth factors and thus
promote cellular growth, survival and by pass the DNA-damage checkpoints. HBV is one
of the Hepadnaviridae families, which is an enveloped DNA virus. It is a very common
viral disease, about 320,000 people die annually due to complications of HBV infection.
Asia and Africa reported to have the highest HBV incidence worldwide 6.In addition,
HCV is a member of the Flaviviridae family which is a single-stranded RNA noncytoplasmic type virus. It is a contagious virus that can contribute to infection by direct
blood contact, perinatal from mother to fetus, and in rare cases, by sexual intercourse.
China, Egypt, and Pakistan have the highest number of HCV cases worldwide7’8. HCV has
been reported to have biological properties compared to HBV, HCV is an associated
hepatocarcinogenetic. Because HCV has a better tendency (60-80%) to produce chronic
infections compared to HBV, which has only a 10% tendency. This tendency is connected
to HCV's ability to generate a fast rate of replication errors that can cause immune evasion.
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1.2.2 Alcohol induced hepatocarcinogenetic
Alcohol consumption is one of the significant causal factors for HCC. Chronic
alcohol addiction causes pre-inflammatory cytokines by activating and disturbing the
monocyte later will lead to an abnormal evaluation circulating endotoxin concentration.
These bring about hepatocyte damage9. In the case of chronic ethanol toxicity, the
hepatocyte demonstrates a high sensitivity to the TNFα cytotoxicity effect, which is a clear
sign of chronic hepatocyte disturbance, activation of the stellate cell, liver cirrhosis, and
eventually10. However, alcohol can affect and damage the liver via a process called
oxidative stress. Three mechanisms can be explaining the connection between oxidative
stress and the liver damage that leads to HCC. First, oxidative stress induces the
progression of cirrhosis and fibrosis, which are considered the main causes of HCC11.
Second, oxidative stress that results from ethanol toxicity has a relevant effect on the HCCsignaling cascade, such as a decrease in the tyrosine phosphorylation of the signaling
transducer and the activator of transcription I (STATI)12.Third, oxidative stress in some
cases increases the rate of telomere shortening which may interrupt the DNA replication
process and cause HCC13. In addition, Alcoholic liver disease (ALD) it’s a factor leads to
cirrhosis and later HCC because (ALD) cause liver injuries such as steatosis, steatohepatitis
and consequently HCC. But generally HCC doesn’t develop in absence of cirrhosis, just in
heavy alcohol intake without cirrhosis it the obvious risk factor in some HCC patients14.
1.2.3 Obesity and type 2 diabetes
Obesity has been found to be a primary risk factor for some cancers including breast
cancer,

endometrial

cancer,

colon

cancer,

renal

cell

carcinoma,

esophageal

adenocarcinoma, and HCC. Extensive studies have confirmed a strong link between
obesity and HCC (Figure 1.2)15. The obesity and type 2 diabetes are the factors causing
the development of non-alcoholic fatty liver disease (NAFLD) and progress of HCC. In
United State the number of NAFLD associated with HCC was reported to increase to 9%.
Beside the role of obesity in HCC, genetic factors also have an essential role in metabolic
syndrome of the obese patients and subsequently to HCC. Increasing the free fatty acids
from triacylglycerol (TG), in obese case will cause the release of tumor necrosis
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factor (TNF-α) from recruited macrophages and decrease secretion of adiponectin which
considered as an insulin sensitizer. So, in the end hepatic lipogenesis is increased due to
induced TG content leading to development of insulin resistance which will cause
stimulation of the transcription factors (SREBP1, ChREBP1) which play role in promotion
of hepatocarcinogenetic.

Figure 1.2 Three putative mechanisms for obesity-induced and obesity-promoted
hepatocarcinogenesis

1.2.4

liver Cirrhosis
Liver cirrhosis is consider as the main reason for HCC development, which is

mainly caused by the most two common liver’s viral infection, HBV and HCV16,17.The
development of cirrhosis usually occurs when patients have a chronic liver disease over a
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period of years, which can be distinguished by a decrease in hepatocyte proliferation as a
sign of liver damage. This causes an increase in the fibrous tissue and a disturbance of liver
cells that leads to the development of liver cancer. Table 1.1 shows the annual percentage
rate of HCC from cirrhosis caused by viruses or liver complications16.
While these results show HCC progression by liver cirrhosis caused via different
liver diseases, the development of HCC may also include additional mechanisms18,16. Many
studies have found the exact mechanism associated with HCC development from liver
cirrhosis, but only a few possible mechanisms have been proposed, including micro- and
macro-environmental changes that induce cellular proliferation and telomerase
dysfunction19.
Table 1.1 Annual Percentages of HCC Incidences Caused by Liver Cirrhosis.
Underlying disease
HCV
HBV
Alcohol liver disease
Nonalcoholic
steatohepatitis
Hemochromatosis
Primary biliary cirrhosis
Autoimmune hepatitis

Annual incidence (%)
1-8
1-15
1
2.6
2-6
2
<0.2

1.2.5 Fungi-induced hepatocarcinogenetic
Mycotoxins are considered a fungal secondary metabolite with different toxic
effects. Aflatoxin B1 one of many mycotoxins is a food contaminant produced by the fungi.
In addition, it is also known as a carcinogen and is involved in p53 mutation and induction
of HRAS oncogene mutation. AFB1 is activated when it is absorbed in the blood circulation
and metabolism to AFB1-exo-8, 9-epoxide. The active metabolite binds to DNA and
damages it, so it can be distinguished by the activation of the P53 protein 1. This DNA
damage has been founded in 30- 60% of HCC patients in AFB1 epidemic regions2.
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1.3 Diagnosis of HCC:
The main challenge in HCC remains the early diagnosis which allows potential
treatment approaches. Various tests used to diagnose HCC, include imaging, histology and
serological tests. Imaging tests, such as ultrasound (US), computerized tomography (CT)
and magnetic resonance imaging (MRI) can be used to detect hepatic nodules20,21. Monitor
and control of cirrhosis in patients of any etiology may decrease tumor-related mortality
22

. Beside the cirrhosis the value of α-fetoprotein (AFP) and newer biomarkers such as

lectin-bound AFP (AFP-L3) as surveillance needed to define their significance23. In
general, gene expression profiles, proteomic and recent progress in metabolomics can act
as potential biomarkers. This will help in the identification of HCC development and may
serve for monitoring therapeutic response22.
1.4 Stages of Hepatocellular carcinoma:
Staging of hepatocellular carcinoma is a critical step in management of patients and
HCC treatment. Because any of these stages should be linking with treatment indication
and this should be based on strong scientific data24. The Barcelona Clinic Liver Cancer
staging system is concluded in figure (1.3)25 which is important to treatment of HCC
patients based on this staging system26.
The BCLC recognizes the following five stages of HCC:
1.4.1

Very early stage (BCLC 0)
This stage can start in patients who have single HCC smaller than 2 cm in cirrhotic

liver without clinically related portal hypertension. Because these small tumors have a very
low chance of microscope dissemination, especially if they were related to indistinctly
nodular type27.
1.4.2

Early stage (BCLC A)
In this stage patients have single HCC or nodules up to three or less than 3cm. The

function of the liver is defined by Child-Pugh A and Child-Pugh B status not reaching the
criteria for transplantation25.
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1.4.3

Intermediate stage (BCLC B)
This stage is characterized by those patients with multifocal/large disease who are

asymptomatic and do not present vascular invasion or extrahepatic spread Liver function25.
1.4.4

Advanced stage (BCLC C)
For this stage is formed by those patients with extrahepatic spread, vascular

invasion and / or mild cancer-related symptoms. Liver function in this stage is not well
confirmed as a prognostic predictor, in addition the presence of ascites may a worse
prognosis28 .
1.4.5

End stage (BCLC D)
This include those patients with severe impairment of liver function (Child-

PughC) who are not allowed for liver transplantation and those who they have heavy
impaired physical condition as established by an ECOG performance status >228.

Figure 1.3 The Barcelona -Clinic Liver Cancer (BCLC)staging system for HCC.
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1.5 Current treatment of HCC:
Treatments for HCC depend on the extent (stage) of the disease as well as the age,
overall health, the type of local medical resources and personal preferences, there are
various treatment choices available for HCC26. Treatment of HCC is divided into two
types; curative and palliative. The curative treatment for HCC treatment include ablation,
surgical resection and liver transplantation; these usually provide a high percentage of
treatment response which increases the survival rate. For the second type, the palliative
options of HCC treatment, such as chemotherapy and radiotherapy, do not tend to provide
a high rate of response compared to the curative options, but they can improve the survival
rate of HCC patients in general29.
1.5.1

Surgical Resection
HCC patients with a non-cirrhotic liver, an early stage of HCC and the liver health

and function are good candidates for the resection surgery. The process of liver resection
it is done by removing the specific part of the liver that has the tumor mass, along with a
small range of liver tissues around the mass, leaving the healthy part of the liver to renew
the whole organ. Among all the HCC treatments choices, surgical resection for the early
stage of HCC is considered the best choice because it provides complete extirpation of the
tumor mass and keeps the liver function regeneration30. But, treatment with surgical
resection has some limitations for curing HCC. First, some clinical tests should be made
on the liver to ensure that the remaining part of the liver has the ability to renew the liver
function. For example, HCC patients with liver cirrhosis are not suitable for surgical
resection. Second, removing the liver tumor mass will not remove the tumor completely,
that means will increase the chances of generating a de novo primary tumor mass. The
statistical studies indicate that 75-80% of HCC patients who have had the tumor mass
removed will survive. Third, if the patient has several tumors the chance of treating HCC
by surgical resection will be small. In addition, the HCC cases that diagnosed at the late
stages with the association of liver cirrhosis will make surgical resection an impractical
option22.
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1.5.2 Liver Transplantation
Liver transplantation is considered one of the best curative treatment options for
HCC patients with one tumor nodule less than 5 cm or up to three nodules each less than 3
cm, especially in the early stages22, since it removes the whole liver including its tumor
masses. It thus provides a solution for the underlying cirrhosis. On the other hand, the main
problem with liver transplantation is the spread of the tumor to another organ. There are
criteria Knows as the Milan criteria, which are criteria used to distinguish HCC patients
who are suitable for liver transplantation. These criteria include: a solitary tumor < 5cm in
diameter, total of 3 lesions <3cm in diameter, and no spread of the tumor to the other organs
or vessels. The Milan Criteria increased the survival rate to 80% and returning survival rate
to 83% after liver transplantation31.
1.5.3

Local Ablation
Local ablation is usually performed in early-stage disease for those who are not

candidates for resection or transplantation22. Ablation therapy provides local management
of the HCC cancer cells with only a small influence on the neighboring cells and other
hepatic tissues. The three types of ablation therapy include radiofrequency ablation (RFA),
percutaneous ethanol injection (PEI) and microwave ablation (MWA). RFA uses an
electrical current with a high frequency to deliver heat to the liver tissues and cause
coagulative necrosis, however, RFA will continue to be the first-line therapy in nonsurgical
patients with small lesion until more effective technique are established. PEI mainly causes
liver cell dehydration, which is responsible for the death of the exposed liver tissues, also
produces coagulative necrosis. Unlike RFA, MWA generates heat by applying an
electromagnetic source to the liver tissues that can cause the tumor masses to die30.That is
why chemotherapy is another option for HCC treatment.
1.5.4 Chemotherapy
The name chemotherapy is referred to a systemic therapy using small molecule
drugs to target various signaling pathways. However, treatment of HCC with chemotherapy
agents has not been very promising to date and suffers from the drawbacks of dose-limiting
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toxicity, developing of multidrug resistance and unfavorable side-effect such as other
cancers. since they have not increased the survival rate. The major reason for this is
multidrug resistance associated with most of the drugs available32. Multiple goals are
possible when using chemotherapy to treat HCC patients, including curing cancer, slowing
cancer growth, and treating cancer symptoms33. In general, four anti-cancer drugs types are
available, including alkylating agents, antineoplastic agents, intercalating agents and
molecular target anti-cancer agents. However, the Food and Drug Administration has
approved only a few drugs for the treatment of HCC (Sorafenib and Erlotinib), which are
considered molecular target anti-cancer agents34.
1.5.5

Radiotherapy
Radiotherapy(RT) is another option for the treatment of HCC. Its application of

radiotherapy has increased recently decades, and also the studies using the latest
technologies, such as stereotactic body radiotherapy (SBRT) or proton therapy has
increased. Many researchers have reported effective clinical outcomes for patients with
HCC using RT. This therapy can achieve necrosis by killing the tumor cells in a small liver
tumor mass. However, radiotherapy has some risks for the patients, such as causing
abdominal injuries or extensive hepatitis. For these reasons, the use of this technique for
treating HCC is very limited35.
1.5.6

Treatment Strategies of HCC by Molecular Target
Treatment of HCC can be done by either liver transplantation or surgical resection

if diagnosed in its early -stages. However, majority of the HCC cases are discovered in the
late stages, which cause poor survival rate 36. The main reason for this decreasing in the
survival rate is the lack of effective chemotherapeutic agents that can cure HCC in its late
stages. Many studies have demonstrated that only 10-20% of HCC patients respond to the
chemotherapy

treatments,

with

toxicity

and

cellular

resistance

to

available

chemotherapeutic agents being the main problem to successful treatment 37. Searching for
new active molecular target anti-cancer agents for HCC has become a popular area for
research due to the urgent need to overcome the toxicity and cellular resistance problems.
In addition, molecular targets is essential for the discovery of a therapeutic treatment that
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overcomes the resistance and decreases the side effects

38

. Hepatocellular carcinoma

(HCC) is a diverse and complex tumor with many variations in genome. Irregular
activation of several signaling cascade has been shown by previous research. For example
epidermal growth factor receptor (EFGR), RAS/extracellular signal-regulated kinase,
phosphoinositol 3-kinase/mammalian target of rapamycin (MTOR), hepatocyte growth
factor/mesenchymal-epithelial transition factor, Wnt, Hedgehog, and apoptotic signaling39
.
1.5.7 Disrupted Signaling Pathways and Targeted Therapies
The molecular aberrations described protein kinase as the main targets for liver
cancer therapy. Description of the whole protein kinases pathway a few years ago has
helped the discovery of new oncology drug .The key signal transduction pathways involved
in the pathogenesis of HCC are Wnt-βcatenin pathway, EGFR-RAS-MAPKK pathway, cMET pathway, IGF signaling, Akt/mTOR signaling, and VEGF and PDGFR signaling
cascades Figure (1.4)40. In addition, targeted therapies developed for these pathways are
summarized in Table(1.2)39.

Figure 1.4 Activation of EGFR leads to downstream signaling pathways that ultimately
drive tumor proliferation or impair apoptosis.
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Table 1.2 Molecular Targeted Agents in Clinical Development in Cancer:
Cancer cell

Target

function

Agent (type)
Gefitinib (TKI), Erlotinib (TKI),
EGFR

Cetuximab (mAb), Panitumumab
(mAb)

Growth factor

HER

receptor
PDGFR
Signal
FLT3

transduction

RAS

Intracellular signaling

Angiogenesis

Growth factor
receptors

Imatinib (TKI), Sunitinb (TKI),
Sorafenib (TKI)
Lestaurtinib (TKI), PKC 412 (TKI),
sunitinib
Farnesyl transferase inhibitor
tipifarnib.
Sorafenib.

MEK

Vandetanib, AZD6244.

VEGF
VEGFR
(1–3)
PDGFR

Apoptosis

(TKI)

RAF

MTOR
Growth factor

Trastuzumab (mAb), Lapatinib

Intrinsic pathway

BCL2

Extrinsic pathway

Apo2L/TRAI

Temsirolimus, everolimus,
rapamycin.
Bevacizumab (mAb)
Sorafenib, sunitinib, Britain,
cediranib, Valatanib, IMC1121B
(mAb)
Sorafenib, imatinib, sunitinib.
GX15-070, oblimersen
Mapatumumab, Apomab, AMG655, rhApo/TRA
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1.5.8

Growth Factor Receptor Signaling:

1.5.8.1

EGFR-Ras-MAPKK Pathway

The EGFR is a member of a family of four related receptors (Her2/Neu, ErbB3, and
ErbB4) that upon ligand binding trigger tyrosine kinase activity and consequently initiate
signal transduction. The function of EGFR classically occurs because of point mutations,
amplification, or increase in ligand-receptor interaction41. Activate of the RAS/MAPK
signaling pathway and induce transcription of genes of the AP1 family, such as c - fos and
c - jun , which play an important role for cell proliferation it’s done by the ligands EGF,
hepatocyte growth factor (HGF), PDGF, and VEGF39. In addition, effective blockade of
the EGFR signaling pathway can be achieved using monoclonal antibodies against EGFR
(cetuximab) or ErbB2/Her2/neu (trastuzumab). In HCC, Ras/MAPK pathway activation
might cause aberrant upstream signals (EGFR signaling, IGF signaling) or inactivation of
tumor suppressor genes by aberrant methylation42.
Therefore, inhibition of the EGFR-TK signaling cascades are promising potential
approach for the treatment of hepatocellular carcinoma (HCC). In the signaling cascade,
both upstream or downstream targets of EGFR can be used for the treatment of any cancer
in general and HCC specifically43’44. Many organic compounds, such Erlotinib, have
shown potent inhibitory activity against EGFR by inhibiting its phosphorylation; these are
known chemotherapeutic agents for the treatment of HCC. Erlotinib (Tarceva) is a very
active and selective inhibitor of the EGRF-TK protein. It has an advantage over most of
the anti-cancer agents in that it can be taken orally, inhibits cellular proliferation and causes
cell cycle arrest at the G1 phase. In addition, it has been approved as an active drug for
pancreatic and lung cancer by the FDA but is still in Phase II clinical trials as an anti-cancer
drug for HCC45.
1.5.8.2

Vascular Endothelial Growth Factor (VEGF)
HCC is as hypervascular cancer and has a large amount of tumor vascularity.

VEGF is connected to the angiogenesis of various cancer types and HCC is one of them
whose progression is enhanced by VEGF46. HCC and all other tumor masses need blood
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vessels to survive and enlarge, as a result these blood vessels are considered abnormal since
they are responsible for the high fluid pressure inside the tumor mass. Therefore, VEGF as
a targeting agent may cause a decrease in the tumor vessels' supplies and their sinuosity
and consider to be a promising target therapy, which leads to a decrease in the internal
pressure of the tumor mass. All of these processes will lead to normal blood vessels 47. In
2005, Gerber et al confirmed the ability of anti-VEGF drugs, in combination with other
anti- cancer agents, to cause a fast decrease in the internal vessel pressure of the tumor
mass, which resulted into faster targeting of the agents to the tumor mass, a decrees in the
tumor size and an increase in the survival rate

48

. A lot of agents have been designed to

treat HCC by targeting VEGF or VEGFR. Some of them have been proven effective, such
as Erlotinib Figure (1.5), and some are still in clinical trials to verify their pharmacokinetic
profiles. Erlotinib is one of the first molecular target drug approved by the Food and Drug
Administration (FDA) for the treatment of HCC. It is considered a multi-kinase agent that
stops tumor cell proliferation by inhibiting different molecular targets, including VEGFR
and PDGFR tyrosine kinases, which produces an anti-angiogenic effect. In addition, it
targets the downstream cascades such as the Raf/MEK/ERK signaling pathway49, 50 Figure
(1.5).
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Figure 1.5 Structures of known Chemotherapeutics that target EGFR for treatment of
HCC.
1.5.8.3

Mitogen Activated Protein Kinase (MAPK) Pathway
MAPK includes, in its downstream, four main kinases Ras, Raf, MEK and ERK

Figure (1-5) which connect to each other by phosphorylation. They play role in cell
division, growth and regulation. These downstream proteins are connected to the upstream
receptors such as PDEFR, EGFR, and VEGFR Figure(1.5)51,52. The MAPK pathway is an
essential player in the growth and survival of HCC cells, which makes it a promising target
for the treatment of HCC39, 53 . ABT-100 is one of the anti-cancer agents in phase II clinical
trials that inhibits the farnsylation process of the protein Ras by inhibiting the enzyme
farnesyl transferase, later leads to a decrease in tumor cell growth51,54 . The family of the
protein Raf includes three members: A-Raf, B-Raf, C-Raf. Hyperactivation of C-Raf (wild
type) in various cancer types, including HCC, was the only reported one, which makes it a
valuable target for treating HCC55. Sorafenib is an approved HCC chemotherapeutic agent
that inhibits B-Raf, C-Raf, FGFR, PDGFR and VEGFR56. The family of the protein MEK
includes two subunits, MEK1 and MEK2have been reported that overexpression of MEK1
and MEK2 lead to an activation of ERK1 and ERK2; in the case of HCC, this could be
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happening in different percentages. For more, it has been proven in vitro studies that the
addition of a MEK1 or MEK2 inhibitor to HepG2 or Hep3B HCC cell lines will inhibit the
autophosphorylation and cause cell apoptosis. MEK inhibitors, including include
Selunetinib, RDEA119 and ASCO2010, are still in phase II clinical trials57.
1.5.8.4

PI3K/Akt/mTOR Pathway
The PI3K/Akt/mTOR pathway has a critical role in carcinogenesis58. Akt can be

activated through tyrosine kinase receptor (EGF or IGF signaling) or through organized
activation of PI3K or loss of function of the tumor suppressor gene PTEN by epigenetic
preventing or somatic mutations. In spite of the role of pAkt in HCC still more
investigation, recent studies have suggested a worse estimate for tumors with activated
Akt59.MTOR is consider as an important mediator of the PI3K-Akt pathway, which acts as
a central regulator of cell growth and proliferation, by sensing nutritional status and
allowing progression from G1 to S phase41. The mTOR pathway is activated in a subset of
HCCs, and its blockade with rapamycin or everolimus inhibits growth in HCC cell lines,
and in experimental models

42

. Many novel compounds (MTOR inhibitor) are recently

being tested in early clinical trials. These molecules (rapamycin and analogs) are already
approved as immunosuppressive treatments after liver transplantation60.
1.5.9

Relationship of Multiple-Drug Resistance and Chemotherapy

Cancer is a serious disease that ranks on the second position among diseases that lead
to death, in 2015 have been found death of one person in every five or six people in the
western countries. It is also responsible for 8.2 million of deaths around the world. Every
year more than 14.1 million cancer cases are revealed, mainly in the developing countries.
For more, people who live with cancer count more than 32.5 million61, 62.
When the cancer cells start to be abnormally fast divided cancer is known as serious
genetic disorder. So, if the abnormal divided cells untreated, it will affect the other tissues
of the body and lead to death. The main available treatments of cancer are
chemotherapeutic agents which can either stop or slow the abnormal fast division of the
cells63,64. The major challenge associated with the available chemotherapeutic agents is the
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drug resistance which involved with 30%- 80% of cancer patients65. Therefore, there is an
urgent need to find a new agent to overcome the chemotherapeutic resistance.
Drug resistance in cancer cells is not related to one anticancer drug, but the whole
available chemotherapeutic agents within the same family can be influenced by the same
mechanism. Some cancer cells that developed drug resistance can be resistance to other
types of drugs that are different in their mechanism of action and structure. This process
defined as multidrug resistance (MDR). This phenomenon might clarify the failure drug
combination to overcome the cancer cell resistance66. There are two main clinical times of
MDR; first one start at the time of treatment and the second is already present at the time
of the diagnosis67.
Various biological reactions represent the first defense for the cells include:
1. Activation of cellular elimination process, cellular uptake process and metabolic
reactions to inactivate the drug process inside the cell, all of these processes will
cause the decrease of the chemotherapy concentration inside the cell (Figure
1.6)68,69.
2. Changes of the drug delivery to the targeted tissues because of different reasons
including poor pharmacokinetics profile of the drug such as absorption,
distribution, metabolism and excretion (ADME)70, 71.
3. Enhance the process of DNA repair71.
4. Structural modification of the targeted tissues72.
All the previous mechanism are extracellular factors that increase the cell anticancer drug
resistance. However, the cellular factors that affect the drug presence inside the cell play a
main role for the cell resistance to anticancer drugs through biochemical changes in the
tumor cells and this process include transport-based MDR known as ATP-binding cassette
(ABC).
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Figure 1.6 Mechanism Involved in increase Drug Resistance towards cancer
chemotherapeutic drugs.
Different transporter proteins are located in the lipophilic membrane of the cell,
which play essential role in the pharmacodynamics and pharmacokinetics of various drugs.
Therefore, massive studies on the transporters have been conducted to identify their
locations, functions, structures, selectivity and cellular distribution73. Cellular MDR
decreases the intracellular concentration of the drugs by enhancing the ATP-dependent
efflux pumps, which is one of the family membranes of ATP-binding cassette (ABC)74.
ATP-binding cassette is considered as the largest transmembrane protein family that
demonstrated wide range of specificity. There are about 49 known human ABC genes,
which are categorized into 7 subfamilies starting with ABC and end with ABCG and the
classification were relay on the arrangement of the domain and similarity of the
sequence66.Many products resulted from the metabolic reactions, lipids and various types
of chemotherapeutic agents are pumped out of the cells through ABC-transporter utilizing
ATP-energy dependent movement processes75. The chemotherapeutic agents that
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commonly affected by MDR process are hydrophobic containing drugs, natural products
such as docetaxel and paclitaxel, anthracyclines (daunorubicin, doxorubicin), antimicrotubule alkaloids (vincristine), antimetabolic agents (6-mercaptpurin, methotrexate,
gemcitabine, fluorouracil), epipodophyllotoxin (teniposide and etoposide) and RNA
elongation inhibitors (actinomycin-D)76,77.
1.5.10 Role of ABC Transporters in Cancer Chemotherapy
Multidrug resistance protein 1 (MRP1)/ ABCC1, MRP2 and breast cancer
resistance protein (BCRP)/ ABCG2/MXR/ABCP

are responsible for MDR78. These

proteins play key role in recognition and transport of a large number of structurally diverse
compounds. Many studies have shown that inhibiting these ABC transporters can prevent
MDR79. The MRP subfamily is, the C subset of the ABC transporter superfamily and it is
composed of thirteen members, and nine of these are primarily involved in MDR80.
Functional characterization, localization, and cloning studies have shown that,
these nine MRPs have been established as ATP dependent efflux transporters for
endogenous substances and xenobiotics. The other three members of the MRP subfamily,
namely ABCC7/cystic

fibrosis

transmembrane

conductance

regulator

(CFTR),

ABCC8/sulfonylurea receptor 1 (SUR1), and ABCC9/SUR2, have no role in conferring
MDR. The role of ABCC7 is to regulated chloride channel, whereas ABCC8 and ABCC9
are intracellular ATP sensors and regulate the specific K+ channel permeability77. The nine
main MRPs can be divided into two groups on the basis of structural topology. One has a
common ABC transporter structure and is composed of two membrane spanning domains
(MSD) with nucleotide binding domains (NBD1 and NBD2) in between (Figure 1.7)81.
These can be referred to as short (MRPs) and include MRP4, MRP5, MRP8, and MRP9
(ABCC4, 5, 11 and 13, respectively). The other group, which includes MRP1,2,3,6and7
(ABCC1,2,3,6and7, respectively), have an additional MSD (MSD0) and are referred
as(MRP)82.
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Figure 1.7 The Location of short (MRP4, MRP5, MRP6, MRP8 and MRP9) and long form
(MRP1, MRP2, MRP3, and MRP7).

1.5.11 Natural products as potential source of biological agents:
Natural products are a good and affordable source for new drug entities. Different
vaccines and biologics have been inspired from natural products structure. Around 48.6%
of the anticancer drugs are natural products or derived from many natural products83.
Later on, many advances in biological screening techniques have allowed the study
of the biological mechanisms and chemical profiles of living systems, which has
encouraged researchers to investigate the pharmacological effects of natural compounds84.
Studies are done to clarify the natural products' synergistic impacts and their clinical effects
on the individual body, which could help provide novel curative approaches to different
diseases85 Including vinblastine, etoposide, paclitaxel, and camptothecin. Plants have been
considered as a source for medicaments because of their availability and it was given either
in a crude extract or a pure ingredients86. One of the most studied natural product that has
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many biological activities is cucurbitacins87.
1.5.11.1 Cucurbitacin
Cucurbitacins natural compounds that extracted mostly from the plant of
Cucurbitaceae family such as Ecballium Elaterium, Genystlus keithii, Cayaponia Tayuya,
Citrillus Colocynthic, Trichosanthes Kirilowii and Ecballium Elaterium85. Cucurbitacins
are highly oxidized tetracyclic triterpenoid. They are characterized by their bitterness and
toxicity88.
Isolation of cucurbitacin have been achieved from different parts of the plant,
including the seed, roots, rhizomes and aerial parts of Cantaloupe, Watermelon, Pumpkin,
Honeydew Melon, Spaghetti Squash and Crenshaw Melon89. Several studies have
confirmed the medicinal activity of the cucurbitacins and their clinical effects. Until this
time cucurbitacin are still used as a treatment in some parts such as Asia, Africa and South
America. Many biological activities have been associated with cucurbitacins and their
glycoside derivatives89,90. Recently, cucurbitacins B, C, Q, and E showed antiproliferative
activity on 8 different cancer cell lines, such as HepG2, MDA-MB-468, MCF-7 and A549.
Several

animal studies demonstrated that cucurbitacins anticancer activity through

apoptosis stimulating activity the inhibition of the Janus kinase (JAK), signaling marker
and activator transcription3 (STAT3) signaling90,91.
1.5.11.2 Structure of cucurbitacins
Cucurbitacins are tetracyclic triterpenoid steroidal carbon skeleton (Figure 1.8). It
is believed that other cucurbitacins are derived mainly from the metabolism of cucurbitacin
B or E by enzymatic reactions92. For example, the metabolism of cucurbitacin B produce
cucurbitacin A, C, D, F, G and H, while cucurbitacin E metabolism gives cucurbitacin I, J,
K, and L. In addition, cucurbitacin B and D can be reduced to 23, 24-dihydrocucurbitacin
B or 23, 24-dihydrocucurbitacin D93. The presence of dimethyl group at C4, isopropyl
group at C24 and unsaturated are considered as a unique feature for cucurbitacins. For
more, there are methyl groups at C9, C13, C14 and C20. Cucurbitacins could be exist in
plants as glycosylated or nonglygosylated94.
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The cucurbitacins four-ring system similar to the structure of a steroid ring94.the
Two common difference between cucurbitacins and steroids structures, are that
cucurbitacins having a gem-dimethyl group at C-4 and a C-10 methyl in C-9.
Cucurbitacins' main structures share common features, such as: 1) the double bond between
C-6 and C-5; 2) a high level of oxidation due to the substitutions of many carbons (C-16,
C-11, C-3, C-2) by oxygen atoms; 3) the presence of hydroxyl groups, α at C-16 and β at
C-20 and C-25; and 4) α-β-unsaturated ketone in the side chain located at C-22, C-23 and
11 C-24. an aromatic ring is a common feature in some of the cucurbitacin derivatives,
such as Fevicordin A95. Additionally, cucurbitacins can be found as free glycone structures
or glycosidic structures by a β-linkage to the hydroxyl moiety from monoside at C-2, C-3
and C-25 or from bidesmosides at C-26 or C-2796.

Figure 1.8 General structures of cucurbitacin and steroid.
1.5.12 Biological activities of cucurbitacin:
1.5.12.1 Cucurbitacins Activity as Anti-inflammatory Compounds
Cucurbitacins anti-inflammatory have been proven via targeting many biological
targets to decrease the inflammation. The cyclooxygenase (COX) enzymes playing an
important role in anti-inflammatory activity of cucurbitacins, especially cyclooxygenase2
(COX-2). In comparing the non-steroidal anti-inflammatory drugs (NSAIDs) and
cucurbitacins, the inhibitory rate for COX-2 by cucurbitacins is less than the NSAIDs; for
example, at 100mM concentrated cucurbitacins B, D, E and I showed inhibitory rates of
32, 29, 35 and 27%, respectively, compared to the COX-2 of NSAIDs such as Refeoxib,
Ibuprofen and Naproxen. The same study has proved the selectivity of cucurbitacins
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towards COX-2, since they do not show any activity on the cyclooxygenase-1 (COX-1)
enzyme97.
1.5.12.2 Cucurbitacins Effect on Filamentous-Actin
Many studies confirmed the activity of cucurbitacins E, I and B on the cytoskeleton,
particularly on F-actin. One of these studies proved that some cucurbitacins derivatives
including cucurbitacin E, stimulate actin cytoskeleton disturbance98. This disturbance
connected with the effect of cucurbitacins on the actin-proliferative action in prostate
cancer cell line. One of the features of cucurbitacin E is that it has a selective inhibition
on F-actin depolymerization, but not on monomeric globular G-actin, by forming a
covalent bond with CYS 257 amino acid residue99.
1.5.12.3 Mitogen Activated Protein

Kinase (MAPK) Pathway Activation by

Cucurbitacins
MAPK pathway is considered one of the key parts in the cellular process, which has
signaling transducing cascade including Ras/B-Raf/MEK/ERK (Fig1.5). A limited
research studies have mentioned the potential biological activities of cucurbitacins
targeting the MAPK pathway. Chean et al. confirmed that cucurbitacin B inhibits the
STAT3 and RAS/B-Raf/MEK/ERK cell downstream signaling cascade using the K562
leukemia cell line100. One more study has been done by Salama and Halaweish via Utilizing
computational semi-flexible molecular docking, MTT cell viability assay and binding
immune assay, demonstrated the ability of several types of cucurbitacins to target MAPK
signaling pathway using mutant B-Raf cell lines101.
1.5.12.4 Cucurbitacins as Potential Modulator for Epidermal Growth Factor Receptors
(EGFR)
EGFR, in human cancer has been proven to be involved in the mutation and deletion
of the cell upstream and downstream targets, which makes EGFR a promising biological
target for different types of human cancer102. Hollbro et al confirmed that ErbB receptors,
a member of the GFR family, are a promising targets for the treatment of different kinds
of cancer103. The activation of EGFR and its downstream cascade has increased the survival
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rate of patients in the late stages of hepatocellular carcinoma as reported by Liovet et al104.
1.5.13 CUCUS-Inspired Estrone Analogs (CIEA)
Cucurbitacins is a group of steroidal-triterpene tetracyclic natural products, which
reported for their anti-cancer activities105. However, cucurbitacins have been reported for
their potent activities, synthesis of these compounds is challenging due to the complexity
of the carbon skeleton and functionalities of these compounds. Recently many studies in
Halaweish’s group started to study cucurbitacins targeting epidermal growth factor
receptor (EGFR)100.
Molecular modeling and docking methods were applied to find potential affinity
between cucurbitacins and EGFR along with downstream proteins cascade including Ras,
Raf, MEK and ERK (Figure1.4). In addition, more studies such as cytotoxicity, western
blot and ELISA were used to prove the molecular docking studies results. Cucurbitacins
confirmed to have activities against different cancer cell lines; however, their activities
don’t show specificity or selectivity toward their biological targets. Gastrointestinal
toxicity is one of the side effects involved with cucurbitacins subjections due to their
cellular activations106. Strong cytotoxicity of cucurbitacins in in-vivo model toward renal
carcinoma demonstrated narrow safety and have been withdrawn from preclinical studies
due to their fatal activity107.The broad biological activities of cucurbitacins, non-selectivity
and toxicities are due to their complex chemical structure108.
Cucurbitacins inspired estrone compounds (CIEA) was accomplished in
Halaweish’s group targeting melanoma109. The success in Halaweish’s group of utilizing
the molecular docking inspired us to model novel analogues to target hepatocellular
carcinoma (HCC).
Due to the similarity in chemical structure, particularly the cyclopentane and the
four-ring system, redesigning and mimicking cucurbitacins utilizing steroids may improve
their biological activities and selectivity. Cucurbitacins side chain, which contain α-βunsaturated ketone, is significant pharmacophore for their biological activities. In addition,
the presence of C-16 hydroxyl group increased the chance of forming H-bond with C-24
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ketone, which may enhance the electrophilicity of the α-β-unsaturated ketone110,111 .
1.5.14 Targeting Epidermal Growth Factor Receptor (EGFR):
Many studies have been done on cucurbitacins as promising EGFR inhibitors is not
favorable sometimes due to availability and limitation. This but has encouraged us to
identify the most significant pharmacophores of cucurbitacins in order to synthetically
modify their main skeleton to increase the selectivity toward EGFR and minimized their
undesirable side effects101.Limited researches and studies on the structure modifications of
cucurbitacins have been conducted including quantitative structure activity relationship
(QSAR) studies of semi synthetic of cucurbitacins by Bartalis and Halaweish111.
Several CIEA have been synthesized by small modifications at C-2 of estrone main
structure by installing sulfamate moiety, changes the biological properties of the estrone
dramatically by blocking the estrogenic activity and performing anti-proliferative activity
in breast cancer cells112. In 2016, Bodnar et al, proved that triazole substitution at C-3
position of estrone enhanced the biological activity as anti-cancer with IC50=0.3-0.9μM
97

. Ahmed et al. 2014 confirmed a potent inhibitory activity of MAPK pathway toward

treatment of melanoma by a substitution on C-17 of the estrone skeleton structure109.
Subsequently, by utilizing molecular modeling, series of modified estrone at C-25, C-17,
C-16, C-11 and C-3 positions were designed and developed to target Epidermal Growth
Factor Receptor (EGFR) toward treatment of Hepatocellular Carcinoma (HCC).

Figure 1.9 Significant positions for biological activities in estrone main structure.
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In our group the molecular docking result on the crystal structure of EGFR showed
an outstanding binding affinity with the CUCUS-inspired estrone analogues containing
various functional groups compare to the known EGFR inhibitor, Erlotinib. Modified
estrone at C-17 with isopropanol enon side chain, methoxy group at C-3 and double bond
at C-16 and C-17 position such as MMA102 and MMA132 demonstrated various binding
mods with EGFR binding pocket. MMA132 and MMA102

MMA102 and MMA132 are diastereomers to each other and showed varieties in
the binding mode with the receptor. MMA132, which possess the stereochemistry of
cucurbitacin D side chain, showed an outstanding binding mode with EGFR by forming
H-bond with MET:769: A, which is same amino acids residues that erlotinib binds to in
EGFR to induce anti-cancer activity by H bonding with the same amino acid MET:769-A;
also, MMA132 perform hydrophobic interactions with the amino acids residues inside the
binding pocket. While MMA102 which has the opposite stereochemistry of cucurbitacin
D demonstrated less binding affinity toward the EGFR binding site only with a
hydrophobic interaction mode with the EGFR binding pocket. This result proved the
significant of assembling the enone side chain with the stereochemistry of cucurbitacin D
(Figure 1.10).
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Figure 1.10 Visual representation of A) MMA102 (orange) B) MMA-132 (blue) in the
EGFR ATP binding site along with Erlotinib (purple).

1.6 Project Objectives:
This project is focused on using cucurbitacins inspired analog as a semi-synthesized
natural product that has inhibitory activity toward the epidermal growth factor receptor
(EGFR) and develop it as drug candidates for the treatment of hepatocellular carcinoma
(HCC). No many studies have defined the activity of cucurbitacins toward EGFR in HCC
cell line. In addition, no cucurbitacin-like compounds have been synthesized and
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biologically evaluated targeting HCC. The main objectives of this project are:
Aim1: Studying the cytotoxicity of natural products or semisynthesized natural
products against Hepatocellular Carcinoma cell line
Aim2: Study of the effect of CIEA chemosensitization of HCC/HepG2 resistance cell line
to chemotherapy drugs (Erlotinib)
Aim3: Study the role of multidrug resistance associated protein (MRPs) against
sensitive HEPG2 cell line and resistant HEPG2R cell line.
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2. Chapter Two
Study the cytotoxicity of natural products or semi-synthesized natural products
against hepatocellular carcinoma cell line
2.1 Introduction
Many natural products, biological compounds, total synthesis or vaccines are used
as the main sources of small organic molecules which know as a drug drugs1. Since the
ancient times, natural products play an important role as resource of medicines. For
instance, some herbs used to be chewing to decrease the pain and some of them used to be
wrapped around wounds to heal it. Using natural products to treat diseases and injuries
known as folk medicine2. Recently, the large improve in developing materials to study the
biological mechanism of all new chemical entities, encouraged researchers to investigate
more in the pharmacological effects of natural compounds to clarify their synergistic
impact and their clinical effects on the body. Natural compounds could be providing novel
medicinal approaches toward a variety of diseases, cancer one of them3.
Hepatocellular carcinoma (HCC) is one of the highest cause of mortality and the
third causing of death worldwide4, 5. It has been reported that Asia and Africa have the
highest report of HCC with high incidence among men. HCC was somewhat rare in the
United States compare to the other countries; however, recently it became one of the main
cause of death in the United States6. HCC is a continuous and slowly progressing disease
that is generally associated with other factors such as cirrhosis, hepatitis C virus (HCV),
and hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and
alcoholic consumption)6, 7. Many therapeutic options are available now for HCC such as
local ablation therapy, surgical resection and liver transplantation8. However, these options
are not viable for late diagnosed patients. Chemotherapeutic drugs such as Erlotinib and
Sorafenib are common treatments for HCC9. In addition, drugs resistance and undesirable
side effects are the most challenge problems associated with these chemotherapy drugs10.
Therefore, there is an urgent need to find a new drug candidate to overcome these problems.
HCC molecular pathogenesis is classified into two main complex mechanisms; 1)
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mutation, which happen in some tumor suppress genes or oncogenes; 2) some diseases or
metabolic disorder such as hepatitis infection, metabolic effects (such as obesity, insulin
resistance, type-2 diabetes), toxin (such as alcohol) that cause tissue damage which lead to
cirrhosis11, 12. Both of these mechanisms have been related with irregularity in different cell
signaling pathways that continue the process of carcinogenic results. From a therapeutic
view, all of these signaling pathways are very significant to treat HCC. Consequently,
growth factors-mediated, angiogenic signaling, epidermal growth factor (EGFR), vascular
endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth
factor (IGF), platelet-derived growth factor (PDGF), and the mitogen activated protein
kinase (MAPK) pathways are the most distinguished targets for treating HCC due to their
noticeable overexpression during the disease Figure 2.113,14.

Figure 2.1 Signaling pathway/molecular targets and new targeted agents under
development in hepatocellular carcinoma.
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Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) figure 3.2 is one of
the tyrosine kinases that has been confirmed in many studies as a promising target for the
treatment of different carcinoma including HCC15. EGFR, which is also known as ErbB1,
is a member of family of growth factor receptors including ErbB2, ErbB3 and ErbB4.
Paracrine or juxtracrine extracellular ligand binding such as epidermal growth factor (EGF)
and transforming growth factor (TGF)-α stimulate the EGFR, which lead to hetro- or homo
dimerization and conformational change that activate the tyrosine kinase and allow
autophosphorylation16, 17 .The phosphorylation is the key role for this signaling pathway
for cancer treatment. When the phosphorylation occurs, number of signaling pathways
activated leading to cancer cell invasions, proliferation, metastasis, inhibitory of apoptosis
and angiogenesis (figure 2.2)18, 19. Therefore, inhibition of EGFR-TK signaling cascades
provides an approach for the treatment of hepatocellular carcinoma (HCC).

Figure 2.2 EGFR signaling pathway in HCC.
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Cucurbitacins (CUCS) (Figure 2.3) are natural products extracted from plant of
Cucurbitacea family such as Gonystylus keithii, Cayaponia tayu, and Citrillus colcynte.
Cucurbitacins plant family first used in folk medicine due its biological significant and
activity as anti-inflammatory agents. There are many types of cucurbitacins classified as
following; A, B, C, D, and E, to T. In addition, hundreds of cucurbitacins derivatives have
been isolated and identified some20. They have been used for treatment of different diseases
such as chronic hepatitis, liver cirrhosis, jaundice, dyspepsia, inflammation and cancer21.
Recently, many studies have shown significant activities of CUCS as potential candidates
for treatment of hepatocellular carcinoma (HCC)22. Current knowledge of molecular
targets and singling pathways of different types of cancers provide a clear understanding
of tumor cell regulation, which in turn paved the way to synthesis promising potential drug
candidates.

Figure 2.3 Structures of Cucurbitacins and Starting Material Estrone.
CUCS demonstrated a wide range of biological activities due to their cytotoxicity
on cancer cells and their potency on different biological pathways. These biological
activities nominate CUCS as a potential drug that targeting multiple types of cancer23.
Cucurbitacin D, isolated from Cucurbita Texan, and 3-epi-isocucurbitacin D prevent client
maturation without induction of the HSR. Cucurbitacin D also disrupted interactions
between Hsp90 and two cochaperones, Cdc37 and p2324.
To avoid the undesirable adverse effects of the natural products and increase their
selectivity, many structural modifications to their structure causes the improvement in their
efficiency25. Therefore, the identification of the most significant pharmacophore of the
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natural products is essential to conduct structural modifications.
What make the CUCS interested in our group is that CUCS has tetracyclic moiety,
they are very similar to that of steroids (Fig. 2.3). However, they in fact that C-10 methyl
is located at C-9, possess a gem-dimethyl group at C-4 and the configuration of ring B and
ring C26 . Due to this the similarity between the core structures of CUCS and steroids, the
concept of hybrid drug design were used to install the essential pharmacophore of the
CUCS into the steroid structure as promising alternative for the complicated functionalized
structure of the CUCS27, 28 . Specifically, using the estrone skeleton as a starting material
to install different functional moieties including the CUCS side chain and other
functionalities has been done by Kopel et al 27. Furthermore, adding various moieties to the
estrone skeleton structure at C-3, such as methoxy and hydroxyl groups, beside the CUCS
side chain at C-17 in the presence of double bond at C16-C17 demonstrate an increase in
the biological activity of these series of compounds toward several targets. The presence
of the double bond at C16-C17 changed the conformation of estrone CUCS-like
compounds which improves its binding affinity towards the EGFR-TK29.
In our group novel CUCUS-inspired estrone analogs with aliphatic side chain such
as MMA102, MMA132 were synthesized by installing the CUCS side chain at C-16 and
C17 of estrone scaffold. Those compounds demonstrated a very promising binding affinity
by making a hydrophobic interaction as in MMA102, which has the opposite
stereochemistry of cucurbitacin D side chain with amino acids residues of the crystal
structure of EGFR binding pocket; while analogue MMA132, which possess the exact
stereochemistry of the side chain of cucurbitacin D, demonstrated an outstanding binding
affinity through hydrophobic interaction with amino acids residues of the EGFR along Hbond with MET: 796:A, which is the same amino acid as that of Erlotinib make H-bond
with and responsible for its anti-cancer activity (Figure 2.4).
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Figure 2.4 Chemical structures of MMA132 and MMA102.
Chemotherapeutic agents, such as erlotinib and lapatinib, have been shown as
potent inhibitor against EGFR by inhibiting its phosphorylation; these are known
chemotherapeutic agents for the treatment of HCC and other types of cancer. Erlotinib
(Tarceva) is a very active and selective inhibitor of the EGRF-TK protein. It has an
advantage over most of the anti-cancer agents in that it can be taken orally, inhibits cellular
proliferation and causes cell cycle arrest at the G1 phase. In addition, it has been approved
as an active drug for pancreatic and lung cancer by the FDA although is still in Phase II
clinical trials as an anti-cancer drug for HCC30.
2.2 Induction of apoptosis by Erlotinib
Apoptosis plays important role in normal tissue development and maintaining the
hemostasis31. Therefore any mutation or any defect in this pathways leads to different
diseases such as degenerative and autoimmune diseases32. Carl Vogt 184233 discovered it
and in 1965 Lockshin and Williams introduced the term programmed cell death 34. Only
after a decade, the term apoptosis was introduced by Kerr et al35. , Two pathways, namely
intrinsic and extrinsic pathway regulate and induce apoptosis (Figure 2.9)36. Caspases
regulates both pathways, which are synthesized as inactive enzymes and converted to
active enzyme by cleavage. The active caspases cleaves different target proteins that are
necessary in DNA repair and cytoskeleton assembly ultimately causing cell death37. The
caspases are classified into two categories, initiators and executioners. Binding of the
ligand such as Fas ligand (FasL) and tumor necrosis factor (TNF) to the death receptor
(DR)38 causes the induction of extrinsic pathway. DRs include TNF-R1, Fas-Apo1, DR3,
TNF-related apoptosis-inducing ligand receptor-1 (TRAIL-1), TRAIL-2 and DR6. The
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death receptors comprise of extracellular cysteine rich domain (CRD) and an intracellular
death domain (DD)39. Upon ligand binding, the receptor undergoes trimerization leading
to the recruitment of initiator caspases 8 and 10 and Fas-associated death domain (FADD)
to the receptor to form the death inducing signal complex (DISC) to amplify the apoptotic
signal. In addition, the initiator caspases undergo autocatalytic activation which activate
the effector caspases 3, 6 and/or 732. Erlotinib induces the apoptosis through the caspase-3
pathway. Erlotinib was confirmed that induced caspase-3 activity increased dosedependently to 300%40. In the cytoplasm which forms apoptosome complex by binding to
Apaf-1 and procaspase 9. This apopotosome complex activate caspase 9 by auto cleavage.
The cleaved caspase 9 cleaves procaspase 3 which is the executioner caspase leading to the
proteolytic cleavage of different cellular proteins inducing apoptosis41.
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Figure 2.5 Intrinsic and extrinsic apoptotic pathway.
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Aim of the Study: Therefore, understanding the antiproliferative activity of Erlotinib
paved the way for studying the antiproliferative mechanism pf potential drug
candidate. The aim of this study to investigate the potential anti-proliferative activity
of CIEA as potential drug candidate for treatment of HCC.
2.3 Erlotinib and cell cycle regulation
Cell cycle is divided into 4 sequential stages (Figure 2.5)42. Cells need longer time
to prepare for DNA replication in S phase rather than doubling their content from protein
and organelles. The cell prepares itself for replication by monitoring the environment and
building their proteins in the two gaps G1 and G2., Depending on the external conditions
and the signals coming from other cells the length of the G1 phase varies from days, weeks
or even years. Cells can enter a resting phase called G0 if the external environment is not
favorable. The cells can enter the S phase once the condition is favorable again. G2 phase
plays important role by checking the quality of replicated DNA, and synthesizing the
proteins required for commitment of mitosis (M phase)43, 44.
DNA damage result in activation of the cell cycle checkpoints by cyclin-dependent
kinases leading to the cell cycle arrest at G1, S and G2/M phase45 . The antiproliferative
potency of Erlotinib in hepatocellular carcinoma cells contributed to the induction of cell
cycle arrest at G1/G0 phase of the cell cycle , that way decreasing the proportion of cells in
S-phase40.
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Figure 2.6 The cell cycle is divided into four phases.
2.4 ERK MAP kinase in G1 cell cycle progression and cancer
One of the key process that convey signals from the cell surface to the nucleus is
the Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein (MAP)
kinase signaling pathway. In the Ras/ERK signaling pathway a variety of extracellular
stimuli induce sequential activation of mainly three protein kinases; Raf, MEK, and ERK
(Figure 2.6)46. ERK is activated by MEK via phosphorylation on both threonine and
tyrosine residues in the TEY sequence. Activated ERK, in turn phosphorylates both
cytoplasmic and nuclear substrates, including many enzymes, cytoskeletal proteins and
transcription factors. Recently, many studies have identified several scaffold proteins and
inhibitors proteins that have potential role in Ras/ERK signaling pathway. These proteins
can modulate the duration, magnitude, and subcellular location of ERK activity which
provide variations in ERK signaling47, 48. There is multiple research which suggests that
the differences in ERK activity generate variations in signaling outputs that will cause
regulation of the cell fate decisions. In addition, interaction with other pathways could also
be crucial for determining signaling specificity. The role of Ras/ERK signaling pathway in
cell cycle progression in G1 phase and cell proliferation is well established49.
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Figure 2.7 The Ras/extracellular-signal-regulated kinase (ERK) signaling pathway.
In Cell cycle progression from G0/G1 to S phase requires activation of the Ras/ERK
signaling pathway which is related to cyclin D induction and consequent retinoblastoma
(Rb) phosphorylation50,51. ERK is phosphorylated and activated by many external stimuli
like growth factors which then translocate from the cytoplasm later to the nucleus, where
ERK phosphorylates and activates several nuclear ERK targets, including transcription
factors such as Elk-1. Therefore, ERK is responsible for the expression of the immediate
early genes, such as c-fos52. The expression of the immediate early genes in turn regulates
subsequent induction of the delayed early genes, including a first class of G1 cyclins, cyclin
D. Upregulation of cyclin D expression results in upregulation of the cyclin D–CDK4/6
complex. Activation of cyclin D–CDK4/6 kinase activity leads to phosphorylation and
inactivation of Rb, which then activates the E2F family of transcription factors and induces
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expression of target genes, including a second class of G1 cyclins, cyclin E53. As a result
of activation cyclin E–CDK2 kinase, it will lead to further phosphorylation and inactivation
of Rb, thus further increase the activity of the E2F family. This positive feedback leads to
the synthesis of proteins required for S phase entry (Figure 2.7)54,55. Therefore, in response
to growth factor stimulation, ERK triggers these sequential events, including sequential
induction of a number of genes, and thereby causes S phase entry.

Figure 2.8 Regulation of G1 cell cycle progression through ERK signaling.
Recently it has been suggested that for inducing S phase entry of quiescent
fibroblastic cells sustained ERK activation, but not transient activation56, 57. It is necessary
to sustain the ERK activity for approximately 2 or 3 h before the onset of S phase 58.Thus,
through ERK activity is a key factor for keeping G1 phase progression. ERK activation can
induce cyclin D expression several hours after growth factor stimulation59. More recently,
Yamamoto et al. from a Genome-wide analyses of transcriptional programs in cell cycle
progression from G0/G1 to S phase have shown that in addition to ERK-dependent
upregulated genes, there are also ERK-dependent downregulated genes60. However, the
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expression level of most of these ERK-dependent downregulated genes is maintained at a
lower level throughout G1 phase, and the decreased expression levels return to the original
levels rapidly if ERK inactivation occurs. It is to be noted that these ERK-dependent
downregulated genes are known antiproliferative genes until the onset of S phase to allow
successful G1 phase progression (Figure 2.8)46. In addition to the mitogenic signals, the
cells also receive varied stimuli such as environmental stresses that induce transient ERK
activation. Transient ERK activation unable to induce sustained downregulation of
antiproliferative genes, therefore these inappropriate stimuli do not cause cell proliferation.
Thus, this mechanism ensures prevention of inappropriate stimuli from causing cell cycle
progression46.

Figure 2.9 Role of ERK-dependent downregulation of antiproliferative genes in G1 phase
progression.
2.5 Materials and Methods
2.5.1 Hepatocellular carcinoma cell lines and the drugs
The human hepatoma cells line, HepG2 were received from ATCC. The cells were
maintained in EMEM (Eagle's Minimum Essential Medium) from (ATCC) with LGlutamine supplemented with 10% fetal bovine serum (FBS) (Atlanta biologicals) and 1%
penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Corning) at 37°C, 5% CO2. The
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passage number range for cells line maintained between 4-13. The cells were cultured in75
cm2 cell culture flask61 .
2.5.2 Cytotoxicity assay
The sensitive hepatoma cells (HepG2) were seeded in 96-well plate as 5*104
cells/mL (100 μL/well). A serial dilution of CIEA compounds were added after overnight
incubation of the cells at 37°C and 5% CO2. DMSO (Acros Organics) was used as a control
(0.1 %). The cells were incubated with the compounds for 48 hrs. After that 15 μL of 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma Aldrich) (5
mg/mL PBS) were added to each well and the plate was incubated for another 4 hrs. The
formazan crystals were solubilized by 100 μL acidified SDS solution (10% SDS/0.01 N
HCl) (Fisher BioReagents). The absorbance was measured after 14 hrs of incubation at
37°C and 5% CO2 at 570 nm by Hidex Sense Microplate readers62
2.5.3 Cell cycle analysis
The study of cellular DNA content and cell cycle distribution are useful to detect
variations of growth patterns due to a variety of physical, chemical, or biological means,
to detect apoptosis, and to study tumor behavior and suppressor gene mechanisms63. In a
given population, cells are distributed among three major phases of cell cycle: G0/G1 phase
(one set of paired chromosomes per cell), S phase (DNA synthesis with variable amount
of DNA), and G2/M phase (two sets of paired chromosomes per cell, prior to cell division).
DNA content can be measured by using fluorescent technique , DNA-selective stains that
exhibit emission signals proportional to DNA mass64. Flow cytometric analysis of these
stained populations is then used to produce a frequency histogram that reveals the various
cell cycle phases. This analysis is typically performed on permeabilized or fixed cells using
a cell-impermeant nucleic acid stain. But it is also possible using live cells and a cellpermeant nucleic acid stain. While the choices for fixed cell staining are varied, there are
only a few examples of useful cell-permeant nucleic acid stains. The Vybrant®
DyeCycle™ Green and Orange stains are DNA-selective, cell membrane permeant, and
nonfluorescent stains for DNA content analysis in living cells. The Vybrant® DyeCycle™
Green and Orange stains (green is the one that was used in this study) are fluorescent upon
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binding to double-stranded DNA. These stains take advantage of the commonly available
488 nm excitation source, placing cell cycle studies on live cells within reach of all flow
cytomatrices. Vybrant® DyeCycle™ Green stain is excited at 488 nm with emission ~520
nm65.
Method A:
The cells were seeded as 2.5*105 cells/mL in a 6-well plate (2 mL/well) and
allowed to adhere overnight at 37°C and 5% CO2. The cells were either incubated with
different concentrations of MMA132 (1, 2, or 4 μM) and MMA102 ( 1.5, 3,and 6 μM )for
24 hrs .The cells were washed twice with ice-cold 1X PBS (Hyclone™ L aboratories ,
Inc)and collected after trypsinzatio66. The cell pellet was washed two times with ice-cold
1X PBS and fixed with ice-cold 70% ethanol overnight at -20°C. After that, the cells were
washed once with ice-cold PBS and the second wash was done with ice-cold PBS-2% FBS.
The cell pellet was re-suspended in 500 μL propidium iodide (PI)/RNase staining
solution(BD Biosciences) for 15 min at room temperature (RT) in the dark and analyzed
within 1 hr by (BD Accuri C6; Becton-Dickinson, Mountain View,CA)67.
Method B:
According manufacturer protocol6817617667676767174, Cells were seeded into six-well
plates at a concentration of 300,000 cells/ well and allowed to attach in culture overnight,
then treated with IC50 values of compounds or positive control (Erlotinib) for 48 h.
Afterwards, cells were washed with PBS and harvested. Cell cycle analysis was
investigated in accordance with the manufacturers protocol with slight modification.
Briefly, Vybrant® DyeCycle™ Green Stain (Thermo Fisher Scientific) was added to 1 ml
of cell suspension at a final concentration of 0.0625 μM. After 45 minutes of incubation at
37˚C, the samples were analyzed by flow cytometry and compared to DMSO-treated cells.
All these experiments were performed on BD Accuri™ C6 flow cytometer (BD
Biosciences, San Jose, CA, USA) using BD Accuri™ C6 software, version 1.0.
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2.5.4 Caspases 3/7 detection
Effect of MMA132 treatment on the expression level of caspase 3 and 9. Cells were
treated with 2 µM of MMA132 at different time points (1hr, 24hr, 48hr). β actin
(ThermoFisher Scientific) was used as a positive control. The apoptotic effect of MMA132
was confirmed by measuring the level of activated caspase 3 and 9 (Santa Cruz
Biotechnology ) and PARP-169.
2.5.5 Cell Migration (Wound Healing Assay)
The cells were seeded into 24-well tissue culture plate at a density that after 24 h of
growth, they should reach ~70-80% confluence as a monolayer. By a new 1 ml pipette tip
the well was gently and slowly scratched across the center. While scratching across the
surface of the well, the long-axial of the tip was always perpendicular to the bottom of the
well. The resulting gap distance therefore equals to the outer diameter of the end of the
tip. After scratching, gently the wells were washed twice with cold 1X PBS to remove the
detached cells. The cells were either incubated with of MMA132 (2μM) and MMA102
(3μM) for different time points (zero time, 1hr, 24hrs, and 48 hrs). The photos for the
monolayer and cell movement were taken by a microscope at different time points. The
gap distance can be quantitatively evaluated using ImageJ software70.
2.5.6 Western blot analysis
The HepG2 protein lysate and western blot method was prepared and done
according to El-senduny et al71.

HepG2 cells were treated with 2 µM and 3 µM of

MMA132 and MMA102 respectively, and incubated for 1, 2, 4, 8, 24, 48 hrs. Briefly, cells
were lysed with 1X RIPA buffer containing protease and phosphatase inhibitors. The BCA
protein assay was used to quantify total protein concentration. An amount of 20 µg was
loaded onto 10% SDSPAGE (ERK, pERK, MEK, pMEK, RAF, pRAF) and 8% SDSPAGE
(EGFR, pEGFR) per well. The protein was transferred onto 0.45micron nitrocellulose
membrane and blocked with 5% BSA, and subsequently incubated with ERK, pERK,
MEK, pMEK, RAF, pRAF and EGFR, pEGFR primary antibodies overnight at 4°C. The
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive
control.
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2.6 Results
2.6.1 Anti-proliferation and Cytotoxicity Effect of CIEA to HepG2 Cell Line
To determine the anti-proliferation activity of CIEA on the HepG2 cell line, the
cells were treated with tested compounds for 48 hrs and viability percentage was
determined by MTT assay. Figure 1-10a and b show the cytotoxic effects of the CIEA on
HepG2 cell lines. Table 1-3 summarizes the IC50 values of each CIEA as the most active
compound against HepG2 cell lines. The anti-proliferation activity of the synthesized
CIEA using MTT cell viability assay starting with compounds that have R-configuration
showed that six CIEA have potent inhibitory activities on HepG2 cell line such as
MMA132, MMA102, MMA290, MMA245, MMA265, and MMA240 compare to the
standard Erlotinib with 25 µM. (Figure 2.10).
In this study, MMA132 and MMA102 were chosen for further investigation
because they are the most cytotoxic CIEA with 12 times activity more than that of Erlotinib
(Figure 2.11).
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Figure 2.10 IC50 curves for MMA132, MMA102 compounds and Erlotinib on HepG2 cell
line compared to DMSO control.
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Figure 2.11 Cytotoxicity of CIEA on the HepG2 cell.
Table 2.1 Anti-proliferation results against HepG2 cell line.
CIEA

IC50 µM

Erlotinib*

25±0.02

MMA132

2±0.01

MMA128

25±0.2

MMA265

16±0.05

MMA240

13±0.01

MMA305

29±0.4

MMA102

3±0.2

MMA287

25±0.4

MMA290

6±0.01

MMA245

3±0.02

* = Reference drug

MMA132
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2.6.2 MMA132 and MMA102 effect on cell cycle distribution
The HepG2 cells were incubated with different concentrations of MMA132 (1 µM,
2 µM and 4 µM) and MMA102 (1.5 µM, 3 µM, and 6 µM) for 24 hrs then the DNA content
was quantified in each phase of the cell cycle. The cells treated with MMA132 were
arrested permanently at G1 phase, even at 1/2 its IC50 value (Figure 2.12). Cells treated
with different concentration of MMA102 were stopped at G1 phase, after increase the
concentration to 6 µM, the cells arrested at G2 phase (Figure 2.14). Cycle arrested at G1
phase was confirmed by detection of ELK/pELK level in the cell lysate by western blot.
The level of pElk was slightly decreased (Figure 2.16). Elk one of ERK signaling pathway
transcription factors, which plays a vital role to G1 regulation53.

Figure 2.12 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. (A) Control
DMSO. (B) 1µM MMA132. (C) 2 µM MMA132. (D) 4µM h and cell cycle analysis was
performed as described in Materials and methods. The data are shown the percentages of
cells in the G1, G2 and S phase. The histograms were analyzed to determine the percentage
of cells in each phase of the cell.
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Figure 2.13 Histogram showing the G1 percentage on HepG2 cell line treated with
MMA132

Figure 2.14 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. Cells were
treated with different concentration of MMA102 (1.5 µM, 3 µM and 6 µM) respectively
compared to DMSO control. The data are shown the percentages of cells in the G1, G2 and
S phase. The histograms were analyzed to determine the percentage of cells in each phase
of the cell cycle.
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Figure2.15 Histogram showing the G1 percentage on HePG2 cell line treated with
MMA102.
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Figure 2.16 Effects of MMA132 and MMA102 on ELK activation. Western blot analysis
of the ELK1; (A) ELK phosphorylation inhibited and change the expression after 24 hrs
which is related to G1 cell-cycle arrested by MMA132. (B) Effect of MMA102 on
ELK/pElk.
2.6.3 Effect of MMA132 and MMA102 on Cell Migration
HepG2 cells were incubated with 2 μm MMA132, 3 μM MMA102, 25 μM
Erlotinib, 0.01% DMSO as a control. Cells were incubated with different treatment.
Pictures were taken for the monolayer on microscope (LEICA DMI 400 B) at different
time points (0, 1 hrs, 24 hrs, 48 hrs). The images showed that HepG2 cell can migrate into
the scratched space in ~24 hours (Figure 2.17). With 2 μm MMA132, 3 μM MMA102 and
25 μm Erlotinib treatment, the wound was still open after 24 hours indicating that inhibit
cell migration or invasion compared to DMSO (control) by MMA132, MMA102 and
Erlotinib. Consistent with these results, the ‘wound-healing’ assays show that parental cells

62
fill the gap completely by 48 hrs with DMSO and the wound was completely healed. By
contrast, gap filling MMA102 and Erlotinib cells was much slower after 48 hrs, in addition
MMA132 was inhibited cell migration 100%.

Figure 2.17 MMA132, MMA102 and Erlotinib inhibit cell migration in wound-healing
assays and the migration of cells in the open space was observed under a phase-contrast
microscope (200) at the indicated times.

2.6.4 Study the effect of MMA132 on apoptosis
Effect of MMA132 treatment on the expression level of caspase 3 and 9 was
investigated. HepG2 were treated with 2 µM of MMA132 at different time points (1 hrs,
24 hrs, 48 hrs) and β-actin was used as a positive control. The apoptotic effect of MMA132
was demonstrated by measuring the level of activated caspase 3 and 9. Cells treated with
MMA132 induced the caspase 9 level after 24 hrs compared to loading control β-Actin.
Also, there is an increase in the caspase 3 level which was confirmed by inhibition of
PARP. Moreover, it was a significant increase in the levels of both caspases 3 and 9
compared to cleaved ones and inhibited the PARP level which is considered as an indicator
for stopping the DNA damage repair which controls the apoptosis (Figure 2.18).
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Figure 2.18 Effect of MMA132 treatment on the expression level of pro- and antiapoptotic proteins. The cells were treated with 2 µM concentrations for 1, 24 and 48 hrs.
β-Actin was used as a loading control. PARP; poly ADP ribose polymerase, Caspase 3 and
Caspase 9.

Figure 2.19 Histogram showing the inducing of apoptosis by MMA132
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2.6.5 Mechanism of cytotoxic and synergetic effects
The vital role of (EGFR) in tumor proliferation and its overexpression in HCCs
have provided the rationale for targeting and interrupting this key signaling network. EGFR
blockade through monoclonal antibodies and tyrosine kinase inhibitors has translated into
promising evidence of clinical benefit in many types of cancer HCC one of them. EGFR is
expressed in a high proportion of HCCs, and EGFR-inhibitors, such as Erlotinib which has
been shown to inhibit HCC growth and metastasis formation in vitro and in vivo72. So,
that’s why is urgently needed to understand the mechanism of RGFR signaling pathway.
The level EGFR/pEGFR, B-RAF/pB-RAF, MEK/pMEK, and ERK/pERK were
detected after treatment of compounds MMA132 and MMA102 with 2 μM and 3 μM,
respectively. MMA132 and MMA102 showed effect phosphorylation forms of RGFR
signaling pathway. It was found that the phosphorylation level of EGFR was decreased
after 48 hrs treatment with MMA132 by 90%. MMA102 inhibited p-EGFR level after 2
hrs of treatment. In contrast, MMA132 showed only slightly effect at pB-RAF after 24 hrs
while MMA102 decreased phosphorylation level of B-RAF after 8 hrs compared to loading
control β-Actin. Moreover, the level of ERK, MEK and their phosphorylated forms were
detected. Both MMA132 and MMA102 Leads to decrease in the level of phosphorylated
ERK1/2 and MEK (Figure 2.20) and (Figure 2.22).
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Figure 2.20 Changes in the expression level of EGFR signaling proteins by MMA132.
HepG2 cells were treated with the indicated time points of 2 μM of MMA132. β-Actin was
used as loading control.

Figure 2.21 Histogram presented the inhibition of EGFRE by MMA132 on HepG2 cell
line.
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Figure 2.22 Changes in the expression level of EGFR proteins pathway by MMA102.
(HepG2) cell lines were treated with the indicated time points of 3μM of MMA132. βActin was using as loading control.

Figure 2.23 Histogram presented the inhibition of EGFRE by MMA102 on HepG2 cell
line.

67

2.7 Discussion
Hepatocellular carcinoma is the most prevalent type of cancer worldwide. Recently,
many evidences have been confirmed that epidermal growth factor receptor (EGFR) is
overexpressed in HCC. Erlotinib (N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-4quinazolinamine) is a standard drug that acts as a potent and reversible inhibitor of EGFRTK activity40. In the present study, MMA132 and MMA102 showed an antiproliferative
effect against HepG2 cell line at a concentration 2 μM and 3 µM, respectively, compared
to the standard drug Erlotinib, EGFR inhibitor, which is 25 μM after 48 hrs incubation.
Furthermore, MMA132 showed the greatest activity (2 µM) which is 12 times more than
Erlotinib 25 µM (Standard drug).
The cell cycle provides a critical understanding for coordination between
proliferation and cell death. HCC cancer cells line cells undergo replication and division
by traversing the tightly regulated cell cycle. Growth factors play a critical role in initiating
signaling events stimulating cell cycle progression, which is crucial for their mitogenic and
tumorigenic effects. Epidermal growth factor receptor (EGFR) and its ligands are
frequently upregulated in human cancers. The oncogenic effects of EGFR include initiation
of DNA synthesis, increase cell growth, invasion, and metastasis48. Specific upregulation
of EGFR results in cell cycle arrest, apoptosis, or dedifferentiation of cancer cells while
downregulation of EGFR signaling has therapeutic benefit clinical studies. Therefore,
better understanding of the mechanisms of regulation and coordination between the cell
cycle and EGFR inhibitor will lead to the development of novel cancer therapies46. The
activity of MMA132 and MMA102 against Hepatocellular carcinoma cells were
demonstrated through cell cycle arrest at G1 phase.
To confirm cell cycle arrest at G1 arrested by MMA132 and MMA102, the
understanding mechanism by which inhibition of EGFR results in apoptosis in HepG2 cells
is needed. In this work, is needed to link the inhibition of the EGFR to the multiple
downstream processes, such as DNA fragmentation, and cleavage of PARP by caspase 3.
These pathways are linking surface receptors to apoptosis39. ELK1 and pELK were
investigated because they have been shown to be involved in the extracellular-signal-
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regulated kinase (ERK) signaling pathway, inhibition of the ERK signaling pathway in cell
cycle progression from G1 to S, inhibit phosphorylation of nuclear ERK substrate, such as
ELK1/pELK46. In addition, EGFR inhibitor such as Erlotinib which is the stander drug in
this study was reported as G1 arrested after incubation of the HepG2 cell line with (1-50
μM) for 24 hrs and led to decrease the proportion of cells in the S phase40 which is similar
to our results. The proportion of the cells in G2/M phase of the cell cycle during incubation
with MMA132 and MMA102 remained nearly unaffected. MMA132 arrested the cell cycle
at G1 phase and inhibited pELK1 after 24 hrs of treatment while MMA102 stopped the
cycle at G1 phase at concentrations 1.5 and 3 μM. Furthermore, increasing the
concentration of MMA102 to 6 μM led to arresting the cells at G2 phase.
In apoptosis, caspase 3 cleaves 116-KDa, PARP-1 into 85 and 24 KDa PARP-1
which are required for DNA repair73. The single DNA strand damage and binds to DNA
leading to the induction of proteins required for base excision repair. Overexpression of
PARP-1 was correlated to the poor prognosis and survival of HCC74. Inhibition of PARP1 is proposed in increasing the sensitivity to DNA-damaging drugs such as Erlotinib75.
MMA132 induced the cleavage of caspase 9 which activates caspase 3 which leads to
inhibition of PARP-1. On the other hand, Huether et al, 2003, investigated that Erlotinib
(EGFR inhibitor) induced activation of caspase 3 after 6 hrs at 50 μm in HepG2 cell line,
while one of our compounds (MMA132) induced caspase 3 at 2μm concentration74. This
clearly demonstrated that our lead novel drug candidate produced the apoptotic effect
through caspase 3 and caspase 9.
MMA132, MMA102 and Erlotinib inhibited the invasive and migration potential
of HepG2 cells at different time points. Inhibition of the hepatocellular carcinoma cells
migration (HepG2) by MMA132, MMA102 and Erlotinib. The wounds were allowed to
heal with DMSO treatment control and the migration was inhibited after 48 hrs with
MMA13276. The data revealed that MMA132 inhibited the cell migration by 100% after
48 hrs treatment which is better than Erlotinib that inhabited the cell migration by 93%
after 48 hrs of treatment.
EGFR signaling pathway involved in progression and initiation of HCC, in
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addition, EGFR plays other roles in HCC including RAS, RAF, MEK, and ERK activation
cascade which leads to induction of transcription of cell proliferation77. To understand the
mechanism of MMA132 and MMA102 in inhibition of EGFR pathway, western blot
analysis was conducted. Both MMA132 and MMA102 showed that the phosphorylation
level of EGFR decreased after 48 hrs. Inhibition of pEGFR lead to downstream signaling
pathway which lead to tumor proliferation78. Also, the significant increase in EGFR
expression after 4 hrs of treatment is supports the idea that the receptor’s expression is
being upregulated in response to the treatment.
RAF in EGFR pathway is involved in regulation of many pathological process, in
addition any overexpression of RAF or activation of phosphorylation RAF is a common
indicator in proliferation of cancer cells78. Both MMA132 and MMA102 inhibited RAF in
phosphorylation form, which will cause inhibition of cell proliferation. Moreover,
activation of MEK and its phosphorylation plays role in the inducing proliferation and drug
resistance79. MMA132 and MMA102 caused inhibition of pMEK in EGFR pathway
against HepG2 cell line. Furthermore, ERK/pERK are related to map kinase, which
regulates cell growth, differentiation, and survival46. CIEA MMA132 and MMA102
inhibited the pERK level while total ERK remains unchanged in both treatment. In general,
this clearly demonstrated that MMA132 and MMA102 significantly inhibit EGFR and
other key proteins that control several cell functions including cell resistance to
chemotherapy.
2.8 Summary and conclusions
This work highlights the anti-proliferative activity of novel CIEA compounds
MMA132 and MMA102 on sensitive HCC cells (HepG2) and the mechanism behind this
effect. Moreover, CIEA increase the apoptotic rate, by inhibition of ERK1/2 signaling
pathways, and induced caspase 3 and caspase 9 and inhibit PARP-1. CIEA compounds
MMA132, MMA102, MMA265, MMA240, MMA290 and MMA245 showed
significantly anti-proliferation activity against HepG2 cell line compared to Erlotinib. In
addition, MMA132 and MMA102 arrested cells at G1 phase which was confirmed by ERK
signaling pathway and inhibited pELK1pathway. Also, MMA132 and MMA102 inhibited
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the whole EGFR pathway as demonstrated through inhibition of the phosphorylation of
key proteins in EGFR pathway. Moreover, it was investigated that MMA132 induced
apoptosis significantly as indicated from induction of caspase 3 (67%) and caspase 9 (87%)
and inhibition of PARP.
Briefly, this study established the antiproliferation mechanism of potential drug
candidate for treatment of hepatocellular carcinoma.
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3. Chapter Three
Study the effect of CIEA chemosensitization of HCC/HepG2 resistance cell
line to Erlotinib

3.1 Introduction

Cancer is known as a one of serious genetic disorder when cells become abnormal
and divided very fast. Therefore, if the abnormal cell division is untreated, it will affect the
other tissues of the body and lead to death1. The major available treatments of cancer are
chemotherapeutic agents, which can either stop or slow the abnormal fast division of the
cells. But, cancer cells have the ability to develop resistance to traditional therapies, and
the increasing spread of these drug resistant cancers require further research and treatment
development2. The major challenge associated with the available chemotherapeutic agents
is the drug resistance which involved 30- 80% of cancer patients Therefore, there is an
urgent need to find a new agent to overcome the resistance to chemotherapeutic agents3.
For this reason, it becomes an urgent need to find a new agent to overcome the
chemotherapeutic resistance.

The phenomenon in which disease become tolerant to pharmaceutical treatments is
known as drug resistances4. This concept originated when the resistance was observed in
bacteria against antibiotics, but since then similar mechanisms have been found to occur in
other diseases, cancer is one of them. Some methods of drug resistance are disease-specific,
while others, such as drug efflux, which is observed in microbes and human drug-resistant
cancers, are evolutionarily conserved2.

Cancer resistance to chemotherapeutic agents is a common reason in patient
mortality and due to poor/early prognosis of cancer5. At present, the approved drugs for
advanced HCC is the multi-kinase inhibitor Sorafenib and Erlotinib, which improve overall
survival of three months in the presence of relevant adverse events6. The high molecular
heterogeneity of HCC participates in adjustment of the effectiveness of targeted therapies7.
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Many studies found that there are two main mechanisms involving in the process
of resistance in EGFR signaling pathway. Firstly, the genetically secondary EGFR
mutations could get rid of the inhibition of respective TKIs. Secondly, activation of bypass
survival tracks via other RTKs or alternative downstream compounds also account for the
acquired resistance8 .( Figure 3.1) and (Figure 3.2) 9.

Figure 3.1 Secondary RTKs-induced EGFR-TKIs resistance. EGFR could trigger
downstream PI3K/Akt and MAPK signaling axes which in turn stimulate the transcription
factors to drive the associated genes expression which are related with proliferation,
angiogenesis, invasion and metastasis. TKIs inhibit EGFR-drive signal transduction by
interacting with the tyrosine kinase domain of EGFR. Other RTKs are involved in the
development of TKIs resistance via EGFR-independent way: 1. Amplification of MET
activates PI3K through transactivating ErbB3; 2. HGF overexpression; 3. ErbB2
amplification; 4. ErbB3 activation; 5. IGF1R activation by IGF binding or IGFBP
reduction; 6. AXL activation; 7. FGFR1 activation.
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Figure 3.2 Alternative downstream compounds-induced EGFR-TKIs resistance. 1. PTEN
loss: suppressed HGR1 downregulates PTEN expression which in general inhibits the
PI3K/Akt activation. 2. PIK3CA mutation-derived abnormal activation of PI3K pathway.
3. BRAF mutation-drive abnormal activation of MAPK signaling axis
3.2 EGFR-independent signaling pathways involved in TKIs resistance
3.2.1 Secondary RTKs-induced TKIs resistance MET amplification:
MET, one of RTKs members family, is increased and correlation the TKIs
resistance in EGFR-dependent cancers, especially in lung cancer and liver. In a gefitinibsensitive lung cancer cells and liver cancer cells, focal amplification of MET was found to
stimulate ErbB3 phosphorylation which in turn activates downstream PI3K/Akt signaling
axis recovering the inhibitory effect of gefitinib on EGFR10. At the same time, ErbB3specific shRNA inhibited the phosphorylation of Akt and controlled the progression of cell
cycle in resistant cells. In addition, gefitinib/erlotinib–resistant lung cancer patients, (22%)
of them were had elevated level of MET and hepatocellular carcinoma patients with classic
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EGFR-activating mutations were reported to have concomitant MET amplification leading
to de novo clinical resistance11. Besides lung and liver cancer, MET amplification-derived
therapeutic resistance was also confirmed in other ErbB-dependent cancers, such as
colorectal cancer, esophagogastric cancer, and ovarian cancer12’13. Nevertheless, the
reason why this mechanism has not been reported in other EGFR resistant cells lines and
cancers is not clear so far especially for HCC patients. Recently , several clinical trials are
conducted to estimate the activity of combining the MET-targeted drugs (MET-TKIs or
MET-MAbs) with EGFR TKIs in the treatment of EGFR-mutant tumor with METamplification14 .
3.2.2 Hepatocyte growth factor (HGF) overexpression:
HGF, is the ligand of MET15. The binding between HGF and MET induced various
biological effects, for instance mitogenic, morphogenic, and antiapoptotic activities
16

.Several studies shown that

the activation of PI3K/Akt pathway behind the TKI

resistance and contribute to the carcinogenesis, proliferation, and metastasis in EGFRmutant lung cancer17. The research implied that HGF could play a crucial role in resistance
to EGFR-TKI18.
3.2.3 ErbB2/HER2 amplification:
In recent studies, there are many inconsistent views concerning the influence of
ErbB2 dysregulation on the sensitivity of tumor cells to EGFR-TKIs19,20. Many recent
studies have confirmed that ErbB2 amplification was recognized as an unacknowledged
mechanism mediating the acquired TKIs resistance of many types of cancer with the
absence of the EGFR T790 M mutation21. Moreover, in cases under the treatment with
Erlotinib, inhibition of ErbB2 with small interfering RNAs (siRNAs) impeded the growth
of PC-9, HCC827, and H3255 cell lines without EGFR T790 M22. Afatinib, a TKI targeting
both EGFR and ErbB2, combined with anti-EGFR antibody could remarkably attenuate
the ErbB2 signaling and in turn resumed the sensitivity of lung cancer and liver cancer to
TKIs in vitro and in vivo22-23.
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3.2.4 ErbB3/HER3 activation:
Resistances to EGFR or ErbB2-TKIs during the treatment of several malignancies
were initiated by ErbB324

,25

.ErbB3 can be transactivated and transphosphorylated by

forming a heterodimers with other ErbB members26. Functionally, ErbB3 plays an essential
role in the removal of

the TKIs-inhibited EGFR or ErbB2 to move and sustain the

activation of typical PI3K/Akt signaling pathway in vitro and in vivo24. Unlike the EGFR
and ErbB2 motivating the PI3K during the adaptor proteins, ErbB3 could bind the p85
subunit of PI3K to activate PI3K directly, involving the priority and spread of the ErbB3drived resistance in TKIs-treated tumors27.
ErbB3 is considered a drug resistance inducer because it is primarily mediated by three
methods. At first, MET amplification was known to endow ErbB3 signaling with persistent
activation and contribute to the resistance to gefitinib in lung cancer cell lines 10. Second,
many researches demonstrated that the ErbB2-ErbB3 heterodimer has an important role in
the stimulation of downstream oncogenic signaling in ErbB2+ breast cancer cells 28. The
role of ErbB2 to the resistance to gefitinib and erlotinib was undermined significantly by
TKIs, signaling activities buffering the inhibitory effects of TKIs on ErbB2 were recovered
through up regulating the production of ErbB3 and weakening the activity of ErbB3
phosphatase 24. Third, when EebB3 binding with its ligand heregulin (HRG) or neuregulin
1 (NRG1), it forms a heterodimer with another ErbB receptor. As a result , the ligandreceptor complex strongly triggered PI3K/Akt axis mediating the resistance to anticancer
kinase inhibitors in various cancers 29, 30. In result of this mechanism the role of ErbB3 in
drug resistance mechanisms, is identified as an encouraging approach to resist drug
resistance31.
3.2.5 IGF1R activation
Activation of IGF1R is another mechanism allowing the gained resistance against
gefitinib and Erlotinib to EGFR- amplified and EGFR-mutant cancer cell lines31.In
addition, the signaling mediated by IGF1R participated in the early stage of TKIsresistance32.
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3.2.6 PIK3CA and BRAF mutations:
Mutational activation of the downstream signaling components, such as PI3K/Akt
or MEK/ERK, which was independent on the EGFR was identified as a novel mechanism
of TKIs resistance33,34. Additionally, BRAF, known as a member of RAS signaling
pathway genes, BRAF was reported to be involved in promitogenic activity and acquired
resistance to EGFR TKIs in lung cancer, colorectal cancer and liver cancer through
activating the MAPK signaling axis35, 36.
3.3 Mechanisms of resistance to third generation EGFR-TKIs
Recently , the third generation EGFR-TKIs, including osimertinib, rociletinib
(CO-1686), HM61713 (BI 1482694), ASP8273, EGF816, and PF-06747775, are widely
known to replace the first generation EGFR- TKIs to overcome the status of drug
resistance36, 37. Subsequently, patients were also resistant to these TKIs after 10 months of
treatment, suggesting that additional mechanisms may reduce the efficacy of these
inhibitors37.
In conclusion in EGFR inhibitors treatment such as Erlotinib, in approximately
50% of cases resistance is associated with further mutation of the EGFR, most commonly
mutation leading to the substitution of methionine for the gatekeeper residue threonine at
position 790 in the kinase domain (T790M). This mutation in turn increases the affinity of
the EGFR kinase domain for ATP, which decrease the competitively to the binding of
EGFR TKIs. Second-generation inhibitors such as afatinib are similarly outcompeted, but
because they bind irreversibly to EGFR, they nevertheless exhibit some activity against
EGFR T790M38. Third-generation EGFR TKIs such as rociletinib (CO-1686) and
osimertinib bind to EFGR T790M with high affinity and have confirmed good activity in
patients with T790M-mediated resistance to first generation EGFR TKIs39. But until this
time, targeted anticancer therapies using small molecules provide significant benefits in
patients with HCC who do not respond well to traditional treatment still challenged because
of drug resistance cancer40.
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Erlotinib is consider as the unique drug treatment for advanced (HCC). It appeared
as a silver lining in combating HCC after decades of search. However, it need many
improvements before any satisfactory outcomes. One of the explanations is the genetic
heterogeneity of HCC, which has led to confirming predictive biomarkers for primary
resistance to erlotinib and sorafenib. This concept is utilized for personalized medicine or
seeking therapeutic strategies such as combining erlotinib with other anticancer agents.
Some of the combinations have already shown better effectiveness than Erlotinib or
sorafenib alone, with good tolerance. In other hand the gained resistance to Erlotinib has
become an interesting topic for many researchers. Since Erlotinib is a multikinase inhibitor,
it targets several cellular signaling pathways but simultaneously or sequentially the
addiction switches and compensatory pathways are activated. Based on the investigated
mechanisms for acquired resistance to Erlotinib, some other molecular targeted drugs have
been applied as second line treatment to treat HCC after the failure of sorafenib and
Erlotinib therapy and more are under evaluation in clinical trials. However, the exact
mechanisms accounting for Erlotinib resistance remains unclear. Further investigation on
the crosstalk and relationship of associated pathways will better our understanding of the
mechanisms and effective strategies for overcoming Erlotinib resistance in HCC 41. The
biggest worry about drug resistance to Erlotinib is increasing as the OS (overall survival
)of HCC patients after Erlotinib treatment was only 2-3 months longer than placebo and
Erlotinib was shown to result in a limited increase in median time to symptomatic
progression and a low partial response rate due to drug the mechanisms of Erlotinib
resistance42. Blocking alternative pathways may provide a promising strategy for
improving the drug sensitivity and overcoming the resistance to EGFR inhibitors.
3.4 Mechanism of resistance to Chemotherapeutic agents
Different biological reactions represent the defense drug resistance mechanism
include: Activation of cellular elimination process, cellular uptake process and metabolic
reactions to inactivate the drug process inside the cell, all of these processes will cause
decrease of chemotherapy concentration inside the cell (Figure 1.6)2,43 and (Figure 3.4)2
.
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3.4.1 Drug Inactivation
Drug activation in vivo includes a series of different proteins interacts with
substances and these interactions can modify, by part of drug partially degrade, or complex
the drug with other molecules or proteins, at the end leading to its activation. For most of
the anticancer drugs metabolic activation is essential to get clinical efficacy. However,
decrease in drug activation can be a worthy cause of resistance development in cancer
cells44. In addition, another source of decrease in the activation of AraC can be downregulation or mutation in this pathway, and this can lead to AraC drug resistance. Other
important examples of drug activation and inactivation include the cytochrome P450
(CYP) system, glutathione-S-transferase (GST) superfamily, and uridine diphosphoglucuronosyltransferase (UGT) superfamily45. Because cancer cells can develop resistance
through decreased drug activation, many anticancer drugs require metabolic activation46.
Another cause of drug resistance can be apoptosis-related proteins. For instance,
apoptosis can be promoted by the tumor suppressor protein p53 (TP53), in response to
chemotherapy. TP53 is mutated in 50% of cancers47. Otherwise, inactivation of P53
regulators, such as caspase-9 and its cofactor, apoptotic protease activating factor 1 (Apaf1), can also lead to drug resistance48. One more important mechanism of drug activation
and inactivation is through direct detoxification and mitogen-activated protein kinase
(MAPK) pathway49. This is observed in the GST superfamily, which is a group of
detoxifying enzymes that function to protect cellular macromolecules from electrophilic
compounds. Increase of GST expression in cancer cells induce detoxification of the
anticancer drugs, as a result will cause less efficient cytotoxic damage of the cells. This
increase is also associated with resistance to apoptosis initiated by a variety of stimuli50.
3.4.2 Alteration of Drug Targets
Another method of development of resistance is through alteration of the molecular
target like mutations or modifications for instance, topoisomerase II is a target for some
anticancer drugs. It is an enzyme that prevents DNA from becoming super under-coiled.
The complex between DNA and topoisomerase II is usually transient, but these drugs
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stabilize it, leading to DNA damage, inhibition of DNA synthesis, and a halting of mitotic
processes. Cancer cells can develop resistance to topoisomerase II-inhibiting drugs through
mutations in the topoisomerase II gene51. One more type of anticancer drug for which
resistance can develop are the one which targets signaling kinases, such as members of the
epidermal growth factor receptor (EGFR) family and down-stream signaling partners such
as Ras, Src, Raf, and MEK. These kinases are constitutively active in certain cancers, and
this promotes uncontrolled cell growth. Mutations is the main cause of over-activation of
these kinases; however, the same effect sometimes results from gene over-expression. In
addition, the long term use of inhibitors targeting this kinase will result drug resistance52.
The increased response rates to EGFR inhibitors in certain liver cancer with EGFR
tyrosine kinase domain mutations are reported with acquired resistance within one year.
An EGFR-T790M gatekeeper mutation was reported in half of all cases53.
3.4.3 Drug Efflux
Drug efflux is considered one of the most studied mechanisms of cancer drug
resistance which involves reducing drug accumulation by enhancing efflux. An important
transmembrane protein belonging to the ATP-binding cassette (ABC) transporter family
are responsible for this efflux in addition to transport of a variety of substances across
cellular membranes. These proteins are present in human cells and all extant phyla.
Although their structure varies from protein to protein (e.g., there are 49 known members
of the ABC family in humans), they can be classified on the basis of presence of two
distinct domains, first is a highly conserved nucleotide binding domain and another is more
variable transmembrane domain2. When a given substrate binds to the transmembrane
domain, ATP hydrolysis occurs at the nucleotide binding site and causes a change in
conformation that pushes the substrate out of the cell. This mechanism plays important role
for preventing the accumulation of toxins in cell54. Such ABC transporters are highly
abundant in liver and intestinal cells, where they protect the cells by pumping all the
harmful chemicals into the bile duct and intestinal lumen. These transporters also function
in maintaining blood-brain barrier55’ 2.
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The constitutive activation of signaling molecules like kinases drives the cell cycle
out of control and results in cancer. Conversely, over-expression of proteins involved in
the MAPK pathway, such HRas, c-Raf, MEK1/2, ERK1/2, which act downstream of
receptor tyrosine kinases, increases the expression of Pgp. While inhibitors of the
extracellular signal-regulated kinases (ERK) pathway down-regulate Pgp expression,
growth factors like EGF and FGF increase it. Interestingly, inhibition of HSP90, a
chaperone protein that stabilizes many signaling proteins, also down-regulates Pgp2.
3.4.4 DNA Damage Repair
Some group of chemotherapy drugs target DNA and directly or indirectly damage
DNA of cancerous cells. In this type of drugs, anticancer drug resistance can develop, in
which cancer cells repair the damaged DNA by DNA damage response (DDR) mechanism
which can reverse the drug-induced damage. For example, platinum-containing
chemotherapy drugs such as Cisplatin cause harmful DNA crosslinks, which can lead to
apoptosis. However, resistance to platinum-based drugs often arises due to nucleotide
excision repair and homologous recombination, the primary DNA repair mechanisms
involved in reversing platinum damage. Therefore, for the DNA-damaging cytotoxic drugs
to be effective there should be the failure of the cancer cell’s DDR mechanisms. Inhibition
of repair pathways used in conjunction with DNA damaging chemotherapy could sensitize
cancer cells and therefore increase efficacy of the therapy56.
3.4.5 Cell Death Inhibition
Cell death by apoptosis and autophagy are two important regulatory events. Although
these processes are antagonistic to one another, they both have a role to cell death.
Apoptosis has two established pathways: an intrinsic pathway mediated by the
mitochondria that involves B-cell lymphoma 2 (BCL-2) family proteins, caspase-9 and
Akt, and an extrinsic pathway that involves death receptors on the cell surface. The intrinsic
and extrinsic pathways merge through the activation of down-stream caspase-3, which
ultimately causes apoptosis2. In several types of cancers, BCL-2 family proteins, Akt, and
other antiapoptotic proteins are highly expressed and down-stream transcription
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modulators like NF-κB and STAT are highly active, making these good targets for drug
development. Because of activation of c-Jun N-terminal kinases (JNK) many cancer drugs
also induce apoptosis, which is downstream of the MAPK pathway57. All of these
mechanisms are contribute in drug resistant, can be effectively treated by using one drug
that makes the cells susceptible to death through the altered expression or regulation of cell
death pathway members in combination with another cytotoxic drug that kills the cells in
their vulnerable states, as a result the apoptosis and autophagy in cancer have a role in drug
resistance have which makes it especially important in the field of drug-resistant cancers58.
3.4.6 Epithelial-Mesenchymal Transition and Metastasis
The epithelial to mesenchymal transition (EMT) is one of the solid tumor become
metastasis mechanism. Metastasis itself is a complex phenomenon that includes changes
in a cancer cell and the stromal cells that change its environment( cell migration) (Figure
3.3)59. It also includes angiogenesis, which is the process responsible to form a new blood
vessel around metastatic tumors. The mechanism of EMT, starts when the cells within a
tumor reduce the expression of cell adhesion receptors, including integrins and cadherins,
which help in cell-cell attachment, and increase the expression of cell adhesion receptors
that induce cell motility. Cell motility is also based on cytokines and chemokines, which
may be released by cells in the microenvironment of tumors or by the tumors themselves.
Additionally, higher expression of metalloproteases on the surface of tumors it is contribute
in clear the road for the cells to move outward, promoting metastasis. The role of EMT in
cancer drug resistance is an emerging area of research60.
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Figure 3.3 Multistep metastatic process of cancer cells. The molecular basis of tumor
progression depends on local invasion, intravasation, survival in the circulation,
extravasation and colonization.
3.5 Role of Epigenetics in Cancer Drug Resistance
Epigenetic modifications are an important set of mechanisms that cause resistance
to cancer treatment and that have not been readily discussed and can also influence
carcinogenesis. Epigenetic classified to two types changes are DNA methylation and
histone modification via acetylation or methylation. DNA methylation consists of methyl
groups binding to cytosines at CG-dinucleotides within regions known as CpG islands,
primarily found in upstream gene promoter regions. But, methylation can occur at other
loci throughout the genome. on the contrary, histone modifications alter chromatin
conformation. For example, histone acetylation opens the chromatin, while deacetylation
closes it. These mechanisms ultimately regulate the expression of genes throughout the
chromosome, and in cancer, this normal regulation is broken. For example, tumor
suppressor genes are often silenced via hypermethylation, and oncogenes are overexpressed via hypomethylation. However, epigenetic mechanisms are usually reversible,
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and researchers may be able to take advantage of this opportunity to develop treatments
that can counteract drug resistant cancers2,61.

Figure 3.4 Depiction of the primary mechanisms that enable cancer cells to become drug
resistant.
3.6 Properties of resistant cells generated from HCC cell lines treated with EGFR
inhibitors (Erlotinib)
Epidermal growth factor receptor (EGFR) signaling plays an important role in HCC
and therapeutics targeted against EGFR have been effective in treating a subset of patients
bearing somatic EFGR mutations. Because, the cancer eventually progresses during
treatment with EGFR inhibitors, even in the patients who respond to these drugs initially.
Recently, many studies have identified that the conquest of resistance in approximately
50% of cases is due to generation of a secondary mutation (T790M) in the EGFR kinase
domain. In about 20% of the cases, resistance is associated with the amplification of MET
kinase. In the remaining 30-40% of the cases, the mechanism underpinning the therapeutic
resistance is unknown61.
In this study We want to determine whether CIEA compounds have Antiproliferation effect against Erlotinib Resistant HepG2 cell line and study the mechanism of
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theses CIEA compounds on EGFR signaling pathway on resistance to Erlotinib by
establishing Erlotinib-resistant cell sub- line from HepG2 cells.
Aim of the study: There for understanding the mechanism and antiproliferative
activity of CIEA against HEpG2-R for studying the effect of CIEA chemosensitization of
HCC/HepG2 resistance cell line to chemotherapy drugs (Erlotinib)

3.7 Materials and Methods
3.7.1 Development of HepG2 resistant cell line
Human sensitive liver cancer cell line HepG2 (ATCC, ManassaVA) was used in
this study to develop the resistance. The cells were maintained in EMEM (Eagle's
Minimum Essential Medium) (ATCC, ManassaVA)) supplemented with 10% FBS
(Atlanta biologicals) and 1% penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Corning)
at 37°C, 5% CO2. During culture, the medium was changed every other day. The cells
were passaged every 5-6 days using Trypsin-EDTA (0.25% trypsin, 1 mM EDTA)
(Hyclone™ L aboratories, Inc). The protocol to develop resistance cell line against
Erlotinib(Selleckchem) was presented by Ghosh et al., 201262, starting with an Erlotinib
(Selleckchem) concentration of 2.5 μM, the exposure dose was doubled every15 days until
a final concentration of 25 μM was achieved , which is the IC50 of Erlotinib that has been
reported against HepG2 cell line . The cells were maintained in continuous culture at 25
μM Erlotinib for 30 days. Then the resistance phenotype of the cells was characterized by
a cell proliferation assay. Cell viability was then measured following exposure to varying
concentrations of Erlotinib.
3.7.2 Cytotoxicity assay
The resistant hepatoma cells (HepG2-R) were seeded in 96-well plate as 5*104
cells/mL (100 μL/well). A serial dilution of MMA132 and MMA102 compounds were
added after overnight incubation of the cells at 37°C and 5% CO2. DMSO (Acros
Organics) was used as a control (0.1 %). The cells were incubated with the compounds for
48 hrs. After that 15 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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(MTT) (Sigma Aldrich) (5 mg/mL PBS) were added to each well and the plate was
incubated for another 4 hrs. The formazan crystals were solubilized by 100 μL acidified
SDS solution (10% SDS/0.01 N HCl) (Fisher BioReagents). The absorbance was measured
after 14 hrs of incubation at 37°C and 5% CO2 at 570 nm by Hidex Sense Microplate
readers63.
3.7.3 Cell Cycle Analysis
According manufacturer protocol64, HepG2-R cells were seeded into six-well plates
at a concentration of 300,000 cells/ well and allowed to attach in culture overnight, then
treated with IC50 values of compounds (MMA132 13 μM and MMA102 20 μM) for 48 h.
Afterwards, cells were washed with PBS and harvested. Cell cycle analysis was
investigated in accordance with the manufacturers protocol with slight modification.
Briefly, Vybrant® DyeCycle™ Green Stain (Thermo Fisher Scientific) was added to 1 ml
of cell suspension at a final concentration of 0.0625 μM. After 45 minutes of incubation at
37˚C, the samples were analyzed by flow cytometry and compared to DMSO-treated cells.
All these experiments were performed on BD Accuri™ C6 flow cytometer (BD
Biosciences, San Jose, CA, USA) using BD Accuri™ C6 software, version 1.0.
3.7.4 Cell Migration (Wound Healing Assay)
The HepG2-R cells were seeded into 24-well tissue culture plate at a density that
after 24 h of growth, they should reach ~70-80% confluence as a monolayer. By a new 1
ml pipette tip the well was gently and slowly scratched across the center. While scratching
across the surface of the well, the long-axial of the tip was always perpendicular to the
bottom of the well. The resulting gap distance therefore equals to the outer diameter of the
end of the tip. After scratching, gently the wells were washed twice with cold 1X PBS to
remove the detached cells. The cells were either incubated with of MMA132 (13μM) and
MMA102 (20μM) for different time points (zero time, 1hr, 24hrs, and 48 hrs). The photos
for the monolayer and cell movement were taken by a microscope at different time points.
The gap distance can be quantitatively evaluated using ImageJ software65
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3.7.5 Western blot analysis
The HepG2-R protein lysate and western blot method was prepared and done
according to El-senduny et al66.

HepG2-R cells were treated with 13 µM and 20 µM of

MMA132 and MMA102 respectively, and incubated for 1, 24, 48 hrs. Briefly, cells were
lysed with 1X RIPA buffer(Thermoscientific™Pierce™) containing protease and
phosphatase inhibitors. The BCA protein assay was used to quantify total protein
concentration. An amount of 20 µg was loaded onto 10% SDSPAGE [ERK, PERK (Cell
Signaling Technology), MEK, pMEK (ThermoFisher Scientific), RAF, pRAF (Cell
Signaling Technology)] and 8% SDSPAGE [EGFR, pEGFR (Cell Signaling Technology)]
per well. The protein was transferred onto 0.45micron nitrocellulose membrane and
blocked with 5% BSA (Sigma Aldrich), and subsequently incubated with ERK, pERK,
MEK, pMEK, RAF, pRAF and EGFR, pEGFR primary antibodies overnight at 4°C. The
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive
control.
3.8 Results and Discussion:
3.8.1 Characterization of an Erlotinib resistant cell line
Human sensitive liver cancer cell line HepG2 from ATCC (Manassas, VA), was
used in this study to develop the resistance properties. The cells were maintained in EMEM
(Eagle's Minimum Essential Medium) supplemented with 10% FBS and glutamine. During
culture, the medium was changed every other day. The cells were passaged every 5-6 days
using Trypsin-EDTA (0.25% trypsin, 1 mM EDTA). The protocol to develop resistance
cell line against Erlotinib was presented by Ghosh et al., 201262, starting with an Erlotinib
(Selleckchem) concentration of 2.5 μM, the exposure dose was doubled every 15 days until
a final concentration of 25 μM was achieved, which is the IC50 of Erlotinib that has been
reported against HepG2 cell line . The cells were maintained in continuous culture at 25
μM Erlotinib for 30 days. Then the resistance phenotype of the cells was characterized by
a cell proliferation assay. Cell viability was then measured following exposure to varying
concentrations of Erlotinib.
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After erlotinib resistant HepG2 cell line (HepG2-R) was generated by progressively
exposing the cells to gradually increased concentrations of Erlotinib according to the
protocol presented, the cells were passed every 5-6 days and developed resistant HepG2
cell line when the exposure dose was doubled every 15 days. Cell treated with 25 uM
showed a full resistant properties to chemotherapy maintained for 30 days in the presence
of erlotinib. Resistant cells to 25 µM erlotinib concentration were used for studying the
mechanism of resistant cells to chemotherapy.
3.8.2 Study Anti-proliferation Activity of Erlotinib and CIEA Compounds (MMA132
and MMA102) to Resistance HepG2 Cell line
To confirm the resistant, phenotype was characterized by determining the antproliferation activity of Erlotinib resistant HepG2 cancer cells, the cells were treated for 48
hrs and its viability was determined by MTT assay. Figure 2-5 shows the cytotoxic effects
of the Erlotinib, MMA132, and MMA102 on resistant cell lines. For the Erlotinib the
resistant cells were characterized by quantifying cell viability at different concentrations
of Erlotinib. Erlotinib showed no cytotoxic activity against HEpG2-R after 48 hrs
incubation with 25 μM, which confirms the resistance properties of HepG2 to Erlotinib.
The IC50 values of MMA132 and MMA102, as the most active compounds against
sensitive HepG2 cell line, were 13 μM and 20 μM respectively against HepG2-R compared
to erlotinib as a standard drug for hepatocellular carcinoma that has no cytotoxic activity
on hepatoma resistant cell line. In addition, both CIEA compound MMA132 and MMA102
have high antiproliferative activity on resistance cells more than Erlotinib on sensitive cells
as candidate compounds. The sensitization activity of each CIEA MMA132 and MMA102
was tested by incubating the cells for 48 hrs (Figure 3.5).
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Figure 3.5 IC50 curves for MMA132, MMA102 compounds and Erlotinib on HepG2-R
cell line compared to DMSO control.

3.8.3 Inhibition of Cell Migration (Wound Healing Assay) by MMA132 and MMA102
against HepG2-R
To investigate whether MMA132 and MMA102 have a role in cell migration and
in vitro invasion on HepG2-R cell line and to determine the affected migration and in vitro
invasion after development of resistant HepG2 cell line, we measured the cell migration in
HepG2-R cells treated with 13 μM of MMA132 and 20 μM of MMA102. In these
experiments, cells are grown to confluency and an incision was made in the center of the
wells. Cells were initially seeded in 6-well culture plates with an artificial ‘‘wound’’
carefully created at 0 h, using a P-200 pipette tip to scratch on the confluent cell. The
relative movement of cells to cover the ‘‘wound’’ was measured after 48 hours. Monolayer
microphotographs were taken at 0 and 48 h. As shown in Figure 3.6, MMA132 inhibited
cell migration and in vitro invasion of HepG2-R cells compared with controls. In addition,
MMA102 still has activity to inhibit cell migration against HepG2-R cell line but less than
the MMA102 activity against sensitive HepG2 cell line.
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Figure 3.6 Wound-healing assay. HepG2-R cells were grown to confluency and a linear
‘‘wound’’ was made with a pipette tip. After 48 hours of incubation in the presence of
DMSO (control) or with 13 μM of MMA132 and 20 μM of MMA102 a microscopic
photograph was taken at zero time and after 48 hrs.

3.8.4 Effects on cell cycle distribution against HepG2-R cell line
In order to better understand the mechanism of CIEA against resistant HepG2 cell
line, we analyzed the distribution of cells in different phases of the cell cycle by flow
cytometry following treatment of cells with different compounds (with 13 μM of
MMA132, 20 μM of MMA102 and DMSO as a control). We found that the resistant cells
started to behave differently from sensitive cells in cell cycle arrest with different treatment
caused cell accumulation in the G2 phase (Figure 3.7). For resistant cells, treatment of
HepG2-R cells with 13 μM of MMA132 led to arrest 44.8% of cells in the G2 phase while
treating with 20 μM of MMA102 led to arrest the cells in the G2 phase by 41.7% compared
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to 38.0% in control. In general, these results indicated that cell cycle progression was
significantly blocked in the G2 phase when resistant cells were treated with MMA132 and
MMA102 respectively comparing to DMSO control.

Figure 3.7 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. Cells were
treated with different concentration of MMA102 (1.5 µM, 3 µM and 6 µM) respectively
compared to DMSO control.
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Figure 3.8 Histogram showing the percentage of cells in the G2 phase.
Table 3.1 cell cycle phases on HepG2 and HepG2-R with different treatment of
MMA132 and MMA102
Cell Cycle Phases

HepG2

MMA132
G1
S
G2

41.0%
37.4%
21.0%

MMA102
G1
S
G2

47.0%
22.0%
31.0%

HepG2-R
26.1%
11.2%
44.8%
30.0%
9.7%
41.7%

3.8.5 MMA132 and MMA102 treatment against HepG2-R lead to an alteration in the
EGFR signaling pathways
The level of EGFR proteins pathway was detected after 13 μM of MMA132 and 20
μM of MMA102 drug treatment. MMA132 showed an effect on the whole EGFR pathway,
and this effect of inhibition started after 24 hrs of treatment for the most proteins pathway.
It was found that the phosphorylation level of EGFR, RAF and MEK were decreased in
the resistant cells (Figure 3.9), which is similar to the inhibition caused by MMA132 in
sensitive HepG2cell line (Figure 2.20). In contrast to, the phosphorylation level of ERK
in resistant cells didn’t show the same inhibition of MMA132 in sensitive HepG2 cell line.
In addition, MMA132 showed a unique effect in EGFR pathway by reduced total EGFR.
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Also, MMA102 (Figure 3.11), leads to a decrease in p-ERK and p-MEK after 24 hrs
treatment in HepG2-R cell line (Figure 3.11).
The Raf/MEK/ERK pathway has different effects on growth, prevention of
apoptosis, cell cycle arrest and induction of drug resistance in cells of hepatocellular
carcinoma. The data revealed that MMA132 and MMA102 inhibited the p-RAF which is
considered as an indicator for inhibition of cell proliferation. Because p-RAF regulates
gene expression, it prevents apoptosis and induces cell proliferation67.
MEK/ERK induced proliferation, drug resistance. MEK also influences
chemotherapeutic drug resistance. Moreover, it has been observed that overexpression of
MEK is associated with a worse prognosis of drug resistance. Both MMA132 and
MMA102 decrease the phosphorylation level of MEK after 24 hrs. also, MMA102
inhibited the p-MEK by 100% after 48, which makes our CIEA as a promising drug
candidate for drug resistance. In addition, ERK in EGFR signaling pathway in caner plays
a vital role in inhibition of apoptosis and increases cell growth. ERK also has an essential
role in regulation of the cell cycle arrest in cancer cell and induction of drug resistance
through inhibition of apoptosis67. From Figure 3.9 and figure 3.11, the data presented that
MMA132 and MMA102 inhibited the phosphorylation form of ERK which means
decreasing the cancer cell growth and inhibiting the drug resistance.
Moreover, targeted inhibition of the central components of this pathway appears to
be an excellent choice for future therapeutic approaches. It has been observed that
overexpression of both the Raf/MEK/ERK in EGFR pathway is associated Drug
resistance74.
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Figure 3.9 Changes in the expression level of EGFR signaling proteins by MMA132.
Western blot analyses of EGFR and downstream signaling pathway activation. The
HepG2-R cells line were treated with the correspondent IC50 of MMA132 (13 µm) for 1,
24, 48 hrs, β-Actin used as a loading control. Each experiment was performed in triplicate.
The values above indicate relative expression level compared with control.

Figure 3.10 Histogram showing the inhibition of EGFR signaling pathway by MMA132
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Figure 3.11 Changes in the expression level of EGFR signaling proteins by MMA102. The
HepG2-R cells line were treated with the correspondent IC50 of MMA102 (20 µm) for 1,
24, 48 hrs, β-Actin used as a loading control. Each experiment was performed in triplicate.
The values above indicate relative expression level compared with control

Figure 3.12 Histogram showing the inhibition of EGFR signaling pathway by MMA102
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3.9 Discussion
Hepatocellular carcinoma (HCC) is the most common histological form of primary
liver cancer, the tumor cells retain the features of hepatocytic differentiation. Erlotinib is
the most effective chemotherapy drugs for HCC treatment. The low levels of survival in
HCC patients is related to resistance of the HCC cell to this drug. This is a big challenge
in HCC treatment in this time68. In the present study, Erlotinib alone showed an inhibitory
effect on sensitive HepG2 cell. Moreover, in this study, development of resistant HepG2
cell line to Erlotinib (standard drug), cells were characterized by quantifying cell viability
at different concentrations of Erlotinib. Erlotinib showed no cytotoxic activity against
HEpG2-R after 48 hrs incubation with 25 μM, which confirms the resistance properties of
HepG2 to Erlotinib and leads to investigate the cytotoxicity effect of CIEA compounds on
resistant HepG2 cells line. The novel compounds MMA132 and MMA102 were effective
on resistant cells more than Erlotinib itself in sensitive cells. Also, MMA132 and MMA102
showed antiproliferative activity against HepG2-R cells with 13 μM and 20 μM,
respectively, after 48 hrs of incubation. This clearly demonstrated that MMA132 and
MMA102 significantly has cytotoxic activity to inhibit resistance to Erlotinib.
MMA132 and MMA102 activity against HCC were through cell cycle arrest at
G2/M phase, which is different from the effect of both MMA132 and MMMA102 on
sensitive HepG2 cells line which was G1 arrest. For resistant cells, treatment of HepG2-R
cells with 13 μM of MMA132 led to arrest 38.0% of the cells in control at G2 phase to
increase 44.8% of cells that are treated with MMA132 in the G2 phase, and to 41.7% with
cells treated with MMA102 after 24 hrs of incubation with 13 μM and 20 μM of MMA132
and MMA102, respectively. In contrast, HepG2 sensitive cells were completely stopped at
G1 phase at different concentration of MMA132 and MMA102. These results indicate that
cell cycle progression was significantly blocked in the G2 phase when resistant cells were
treated with MMA132 and MMA102, respectively, comparing to DMSO control. Zhai at
al., in a different study have found that in HepG2 resistant to adriamycin (ADM), the
number of cells in S-phase and G1 was significantly decreased (5. 6%) in HepG2/Adm
while those G2-phase increased (24%)69.Change the behavior of resistance cells in cycle
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arrest to stop the cell cycle at G2 phase confirmed the resistance properties of cells to
Erlotinib.
Inhibition the cell migration of resistant hepatocellular carcinoma cells (HepG2-R)
by MMA132 and MMA102, the wounds were allowed to heal with DMSO treatment
control and the migration was inhibited after 48 hrs with both MMA13 and MMA1022.
Furthermore, we measured the cell migration in HepG2-R cells treated with 13 μM of
MMA132 and 20 μM of MMA102. It was found that MMA132 inhibited the cell migration
and in vitro invasion of HepG2-R cells compared with controls. In addition, MMA102 still
has activity to inhibit cell migration against HepG2-R cell line but less than sensitive one.
Generally, in Comparison with Erlotinib in sensitive cell, MMA132 treatment with
resistance HepG2 cell line has activity to inhibit the cell migration after 48 hrs more than
Erlotinib in sensitive cell.
The effect of MMA132 and MMA102 on the EGFR pathway against HepG2-R was
different form sensitive cells. MMA 132 doesn’t have a clear activity in inhibition of the
phosphorylation level of ERK, which clearly demonstrated the behavior of cell cycle arrest
at G2 phase because the role of ERK pathway to regulate G1 phase. In contrast MMA132
has a huge inhibition on total EGFR and p-EGFR. It also inhibited the phosphorylation
level of MEK and RAF while MMA102 decreased the pERK1/2 and PMEK levels in the
resistant HCC cell line. Hence, these results show the effect of CIEA on the EGFR
signaling pathway in HepG2-R.
MEK/ERK induced proliferation, drug resistance. MEK also influences
chemotherapeutic drug resistance67. Moreover, it has been observed that overexpression of
MEK is associated with a worse prognosis of drug resistance. Both MMA132 and
MMA102 decrease the phosphorylation level of MEK after 24 hrs, and MMA102 inhibited
the p-MEK by 100% after 48, which make our CIEA a promising candidate drug for drug
resistance. In addition, ERK in EGFR signaling pathway in caner plays role in inhibit the
apoptosis and increases cell growth. The data presented that MMA132 and MMA102
inhibited the phosphorylation form of ERK which means decreasing the cancer cell growth
and inhibiting the drug resistance.
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In conclusion, this study confirmed the antiproliferative activity of MMA132 and
MMA102 in drug resistance and demonstrated the mechanism of potential drug candidate
for treatment and solve the drug resistant in hepatocellular carcinoma.
3.10 Summary and conclusions
Our study indicates that prolonged exposure of the Hepatocellular carcinoma cell
line HepG2 to erlotinib selects for a subpopulation of erlotinib resistant cells which are
enriched in stem cell markers and possess stem cell properties in vitro. Furthermore, these
cells were found to be less sensitive to erlotinib treatment as determined by cell viability.
Resistant HepG2 showed resistant properties to erlotinib after 3 months of maintenance in
Erlotinib. HepG2 cells also showed decrease in the number of cells in G1 phase from 38%
in control to 26.1% in MMA132 treatment and 30.1 in MMA102 treatment which is
different from the sensitive HepG2 cell line. Our studies indicated that both MMA132 and
MMA102 inhibit the HepG2-R cell migration after 48 hrs of incubation.
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4. Chapter Four
Study the role of multidrug resistance associated proteins (MRPs) against sensitive
HEPG2 and resistant HEPG2R cell lines

4.1 Introduction
Cancer cells have ability to develop resistance to structurally and mechanistically
unrelated drugs over a period of time1.

Chemotherapy is one of the major

treatment modalities available for cancer patients. Unfortunately, during this course of
treatment, cancer cells start develop

resistance to functionally and structurally

different anticancer drugs by either acquired (due to host factors) or intrinsic (due to
genetic or epigenetic) mechanisms2 . Later on, when the cells selected for resistance to a
single cytotoxic drug, tumor cells may become resistant against an entire range of drugs
with different chemical structures and cellular targets, a phenomenon called multidrug
resistance (MDR)3.
Many studies about MDR suggested that drug transport is a carefully controlled
process, and this process was later found to be regulated by members of the ATP binding
cassette (ABC) transporter family of proteins. P-glycoprotein (P-gp)/ABCB1 was the
first identified ABC transporter4 . In addition, this protein has been confirmed to play a
role in many cellular functions. Recently, has been identified 49 different ABC
transporters in humans, though there are more in bacteria and parasites5 .
ABC transporters have been identified into seven subfamilies, ABCA to G,
depends on sequence similarities. Of them the major ABC transporters involved in MDR
development are ABC subfamily B member 1 [(ABCB1/P-glycoprotein (P-gp)],
ABC subfamily G member 2 [ABCG2, also known as breast cancer resistance protein
(BCRP)/mitoxantrone resistance protein (MXR)/placenta-specific ABC protein (ABCP)],
and ABC subfamily C member 1 (ABCC1/MRP1)6 .
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The ABC transporter superfamily includes membrane proteins that include a wide
variety of substrates across cellular membranes. An increasing number of
chemotherapeutic drugs transported by ABC transporters have been recognized since the
discovery of P-gp 1 (Figure 4.1)7.

Figure 4.1 ABC transporters proteins in multidrug resistance that mediate
chemotherapeutic drug resistance.

The MRP subfamily, the C subset of the ABC transporter superfamily, is classified
to thirteen members, and nine of these are primarily involved in MDR (Table4.1)8.These
nine MRPs have been established as ATP dependent efflux transporters based on
functional characterization, localization, and cloning studies for endogenous substances
and xenobiotics. The other three members of the MRP subfamily, namely ABCC7/cystic
fibrosis transmembrane conductance regulator (CFTR), ABCC8/sulfonylurea receptor
SUR1), and ABCC9/SUR2, are not involved in conferring MDR2. The role of ABCC7 is
to regulate chloride channel, whereas ABCC8 and ABCC9 are intracellular ATP sensors
and regulate the specific K + channel permeability9 .
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Table 4.1 Summary of MRP members involved in MDR
MRP
Member
MRP1
MRP2
MRP3

Alternative name
ABCC1
ABCC2, cMOAT,
cMRP
ABCC3, MOAT-D,
cMOAT-2

Amino acid
identity with
MRP (%)
100
50
58

MRP4

ABCC4, MOAT-B

41

MRP5

ABCC5, MOAT-C,
Pabcc11

38

Tissue
distribution
Ubiquitous
Liver, kidney, gut
Liver, pancreas,
kidney
Prostate, lung,
muscles
Ubiquitous

The nine main MRPs can be classified into two groups. One has a typical ABC
transporter structure and is composed of two membranes spanning domains (MSD) with
nucleotide binding domains (NBD1 and NBD2) in between (Figure 1.7). These can be
referred to as a “short MRPs” and include MRP4, MRP5, MRP8, and MRP9 (ABCC4, 5,
11 and 13, respectively). The other group, which include MRP1, 2, 3, 6 and 7 (ABCC1, 2,
3, 6 and 7, respectively), have an additional MSD (MSD0) and are referred as “long MRP10.
Many studies have been confirmed that overexpression of MRP1 is associated with
an increased transport rate of a range of substrates that are conjugated to glutathione (GSH),
glucuronide, or sulfate11,12. This transporter mechanisms are known as glutathione
conjugate (GS-X) pumps, or multi-specific organic anion transporters3. Besides organic
anions MRP1 can also transport neutral and basic cytotoxic drugs not known to be
conjugated to GSH or other negatively charged compounds13. Notwithstanding, MRP1
requires the presence of intracellular glutathione for the transport of these drugs. It is
credible that MRP2 could play a role in drug resistance, just as MRP1 does. Studies with
mutant rats (TR– /GY or EHBR) that lack the MRP2 protein in the hepatocanalicular
membrane and transfection studies with MRP2 cDNA showed that the substrate specificity
of MRP2 is very similar to that of MRP114, and suggested that MRP2 is able to transport
several anticancer drugs15.
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4.2 ABC transporters as multidrug resistance mechanisms
The adenosine triphosphate (ATP)-binding cassette (ABC) transporters are found
in all organisms. These transporters proteins have been reported to have a role in multidrug
resistance in cancer. ABC transporters were so named because of the presence of a
conserved ATP-binding domain which provides the energy required for a conformational
change16.
Figure 4.2 explains the general drug efflux mechanism of MDR transporters in
cancer cells. First, the anticancer drug molecules penetrate the plasma membrane through
passive diffusion (Figure 5.2a). Next the drug molecules bind to the TMDs, the NBDs are
activated. Subsequently, ATP hydrolysis causes a major conformational change of the
MDR transporter, which ultimately transports the drug molecules into the extracellular
space (Figure 5.2b). This active transport of chemotherapeutic drugs out of the cell,
severely reduces the amount of drug molecules accumulated in the cancer cells and the
effectiveness of chemotherapy17.
The protection of normal tissues such as kidney, liver, pancreas, and the
endothelium of blood vessels of the brain is the vital role of ABC transporters. Among
these transporters, the ones that are most likely to mediate chemotherapeutic drug
resistance are permeability-glycoprotein (P-gp), multidrug resistance-associated protein-1
(MRP1) and breast cancer resistance protein (BCRP) (Figure 1.5)18.
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Figure 4.2 S diagram of the general drug efflux mechanism of an MDR transporter in the
plasma membrane of a cancer cell. (a) Drug molecule enters the plasma membrane through
passive diffusion. (b) The efflux pump, energized by the hydrolysis of a bound ATP
molecule, ejects the drug molecules out of the cell. Redrawn based on the schematic
diagram published in Cancer Control.
4.3 MRP2/ABCC2
MRP2 is the second member of the MRP subfamily of ABC transporter. The first
time MRP2 was cloned from rat hepatocyte and was named as a hepatocellular canalicular
multiple organic anion transporter (cMOAT)19. In addition, MRP2 shares 49% amino acid
identity with MRP1 but it has a different expression pattern. While MRP1 is widely
expressed in many tissues, MRP2 is mainly expressed in the apical (canalicular)
hepatocyte plasma membrane, small intestine, and renal proximal tubules (Table
1)2. mRNA is present in the peripheral nerves, gallbladder, placental trophoblasts, and
CD4 + lymphocyte2, 20,21.
Because of the similarity between MRP2 and MARP1, it was believed to
confer resistance to similar anticancer drugs as well. This hypothesis was created based on
an experiment in which an antisense RNA construct was introduced into human
hepatocellular carcinoma HepG2 cells, causing in increased sensitivity to several
anticancer drugs such as cisplatin, vinblastine, sorafenib, doxorubicin, and Erlotinib19.
MRP2 have been demonstrated TO transport vinblastine in polarized Madin Darby
canine kidney epithelial (MDCK) cells, proposing a potential role for MRP2 in vresistance.
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In addition, transfected cells also conferred resistance to cisplatin, etoposide, doxorubicin,
and epirubicin .This phenomenon is convincible to suggestion a potential role for MRP2
in drug resistance such as Erlotinib against HepG2 resistance cell line15.
The expression of MRP2 has been reported in several human tumor cell lines of
lung, gastric, renal, and colorectal cancers22 . Moreover, few cisplatin and doxorubicin
resistant cell lines have shown overexpression of MRP223. Recently, Korita24, suggest that
efficacy

of

cisplatin-based chemotherapy

in

patients

with

hepatocellular

carcinoma depends upon MRP2 expression level24.
4.4 Physiological and pharmacological function of MRP2
Many studies have been confirmed that MRP2 is important from a pharmacological
function. Firstly, MRP2 has essential role in the intracellularly formed glucuronide and
GSH-conjugates of clinically important drugs25. Secondly, MRP2 is inhibition of the ATPdependent excretion of bile also involved in the biliary excretion of non-conjugated anionic
drug26. For example, the efﬁcient biliary excretion of pravastatin, an HMG-CoA reductase
inhibitor, this process is mediated by MRP227. After exhibiting its pharmacological action
in the liver, pravastatin is then excreted into the bile via MRP2 without metabolic
conversion28. Thus, efﬁcient biliary excretion by MRP2 plays an important role in the
entero-hepatic circulation, which is responsible for maintaining signiﬁcant plasma
concentrations of drugs. The mechanism for the substrate recognition by MRP2 still
remains to be clariﬁed, although Han et al.29 suggested the importance of the non-polar
surface area in determining the afﬁnity using a series of methotrexate analogues29.
Many tumor tissues have been reported that MRP2 is also expressed in some of
them

such as ovarian carcinoma30, colorectal carcinoma31, leukemia32, and

hepatocarcinoma33. Since the transfection of MRP2 cDNA to mammalian cells results in
the conquest of drug resistance against antitumor drugs such as etoposide, vincristine,
cisplatin, doxorubicin, Sorafenib and Erlotinib34, it is possible that the tumor cells
overexpressing MRP2 gain the multidrug resistance. For example , in colorectal carcinoma,
a signiﬁcant correlation has been observed between MRP2 mRNA levels and cisplatin
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resistance , Although it has been assumed that GSH is required for the excretion of P-gp
substrate antitumor drugs , the precise mechanism for the transport still remains un clear35.
Depends on all these previous studies, we hypothesized that MRP2 expression level
in HepG2-R to Erlotinib should be increase.
Aim of this study: Therefore, is convincible to suggestion a potential role for MRP2
in drug resistance such as Erlotinib against HepG2 resistance cell line and Studying the
role of multidrug resistance associated protein (MRPs) against sensitive HEPG2 cell line
and resistant HEPG2R cell line.
4.5 Material and Methods
4.5.1

Detection of expression levels of MRP2 on sensitive and resistant HepG2 cell
line
Western blot analysis of HepG2 protein lysate for resistant and sensitive cells line

were prepared and done as previously described in western blot method page 63. Cells
were lysed without any treatment with 1X RIPA buffer(Thermoscientific™Pierce™)
containing protease and phosphatase inhibitors (Thermo Scientific™). The BCA protein
assay was used to quantify total protein concentration. An amount of 20 µg was loaded
onto 8% SDSPAGE per well, blotted onto 0.45micron nitrocellulose membrane for 120
minutes at a current of 400mA. Because MRP2 is a large protein ,10% methanol was used
in the transfer buffer instead of 20%. Subsequently, blocking was done with 5% BSA
(Sigma Aldrich), and incubated with MRP2 primary antibodies overnight at 4°C. The
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive
control.
4.5.2

Study the proliferation effect of MK571 on HepG2-R alone and in combination
with MMA 132 and MMA 102
The resistance HepG2-R cancer cells (A2780) were seeded in 96-well plate as

5*104 cells/mL (100 µL/well). A serial dilution of MK571(Cayman Chemical (Ann Arbor,
MI) was added after overnight incubation of the cells at 37°C and 5% CO2 at a final

122
concentration of 25 and 15µM, and DMSO (Acros Organics) was used as a control (0.1
%). The cells were incubated with the MK571 for 48 hrs. After that 15 µL of 3-(4,5dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) (5 mg/mL PBS)
(Hyclone™ L aboratories, Inc) were added to each well and the plate was incubated for
another 4 hrs. The formazan crystals were solubilized by 100 µL acidified SDS solution
(10% SDS/0.01 N HCl) (Fisher BioReagents). Absorbance was measured after 14 hrs of
incubation at 37°C and 5% CO2 at 570 nm by Hidex Sense Microplate readers
The resistance HepG2-R cells were seeded as in cytotoxicity assay and incubated
with MMMA132 and MMA102 for 24 hrs followed by addition of serial dilutions of
MK571 (15 µL) then incubated for a total of 48 hrs. The viability of the cells was measured
by MTT. The control was cells treated with DMSO36.

4.6 Results
4.6.1

Detection of expression levels of MRP2 on sensitive and resistant HepG2 cell
line
The level of MRP2 was detected in HepG2 protein lysate for both resistant and

sensitive cells line. Cells were lysed without any treatment. Western blot of resistance
HepG2-R protein lysate demonstrated that MRP2 was highly expressed in HepG2-R about
93% than sensitive cells. In contrast to the sensitive cells, the western blot of protein lysate
for sensitive HepG2 showed lees level expression of MRP2 to be about 44% (Figure 4.3).
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Figure 4.3 MRP2 expression level on resistant HepG2 and sensitive HepG2.

4.6.2

Study the proliferation effect of MK571(MRP1, MRP2 inhibitor) on HepG2-R
alone and in combination with MMA 132 and MMA102
To determine the proliferation effect of MK571 (MRP1, MRP2 inhibitor) alone and

its effect on combination treatment with CIEA analogs (MMA132 and MMA102) on the
resistant hepatocellular carcinoma cancer cells, the cells were treated for 48 hrs with
MK571 at a final concentration of 25 and 15 µM, and viability was determined by MTT
assay. Figure 4.4 and table 4.2 show the cytotoxic effects of the MK571 on resistant
HepG2-R cell lines. The IC50 values of each MK571 were 18.5 µM on both concentration
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of MK571 (25 µM and 15 µM). After that, the proliferation activity of each MMA132 and
MMA102 combined with MK571 was tested by pre-incubating the cells with MMA132
and MMA102, according to their respective IC50 values against HepG2-R (13 µM
MMA132 and 20 µM MMA102), followed by incubation with serial dilutions of MK571.
It was found that the most notably enhanced cell death was evident in cells treated with
MMA132 (13 µM) combined with 15 µM of MK571 inhibitor, IC50 value was about 10
µM, comparing to MMA132 alone and MK571 alone on HepG2-R. In this case the
presence of MK571 led to enhance the effect of MMA132 on HepG2-R and reducing cell
viability after 48 hrs. With MMA102, MK571 did not have any effect in these cells line
HepG2-R.
From our data, MMA132 has antiproliferative activity on multidrug resistance
against HepG2-R cell line alone more than the stander MRP2 inhibitor MK571. It’s 13 µM
compared to MK571 (18.5 µM). Additionally, when it has been combined with MRP2
inhibitor, the cytotoxicity increased to 10 µM. In general, all these results make our CIEA
as a promising potential novel drug candidate that play a role for MRP2 in drug resistance
such as Erlotinib in this study against HepG2 resistance cell line.
Table 4.2 antiproliferation result against HepG2-R

Compound

IC50(µM)

MK571 (25µM)

18.5

MK571 (15µM)

19

MMA132+MK571

10

MMA102+MK571

18

MMA132

13

MMA102

20
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Figure 4.4 Cells pretreated with 13 µM and 20 µM of MMA132 and MMA102,
respectively, then treated with serial dilutions of MK571. The total incubation time was 48
hrs. The cells treated with DMSO as a control.
4.7 Discussion
Previous studies showed that MRP2 plays a role in drug resistance, just as MRP1
does. Because MRP2 handles a wide range of conjugates similar to that of MRP1, it was
believed to confer resistance to similar anticancer drugs as well20. Moreover, it has been
suggested that MRP2 interfere in transporting several anticancer drugs15. In the present
study, MRP2 expression level was different in comparison of sensitive cells to resistance
cells.
MRP2 expression level was extremely low in sensitive HepG2 cell line and
expressed two times less than resistance cell 44%. In contrast, the expression level of
MRP2 was increased in resistant HepG2 cell line to Erlotinib 93% comparing to β-Actin
as loading control. It has been reported before by Charls et al,2000, that MRP2 has been
expressed in sensitive HepG2 cell line by western blot37.

126
In addition, it was found an antisense RNA construct was introduced into human
hepatocellular carcinoma HepG2 cells, resulting in enhanced sensitivity to several
anticancer such as cisplatin2.
These findings indicate that MK571 (MRP2 inhibitor) alone showed an inhibitory
effect on resistant HepG2-R cancer cell lines 18.5 µM. Moreover, the combination of 13
µM of MMA132 with 15 µM of MK571 leads to a significant increase in the inhibitory
effect of MK571 from 18.5 µM to 10 µM. These combinations of drugs were less
effectively with MMA102 (20 µM) and the data showed almost no change of MK571
activity after this combination.
MMA132 showed a potential inhibitory activity when it combined with MK571
against HepG2-R as MRP2 inhibitor to enhance the activity of the stander inhibitor from
18.5 µM to 10 µM after 48 hrs incubation.
The difference in structure and functional between MMA102 and MMA132 which
makes MM132 more active biologically, that MMA132 and MMA102 are diastereomers
with binding mode with the receptor. MMA132, which possess the stereochemistry of
cucurbitacin D side chain, showed an outstanding binding mode with EGFR by forming
H-bond with MET:769: A, which is same amino acids residues that erlotinib binds to in
EGFR to induce anti-cancer activity by H bonding with the same amino acid MET:769-A.
Also, MMA132 has hydrophobic interactions with the amino acids residues inside the
binding pocket while MMA102 which has the opposite stereochemistry of cucurbitacin D
demonstrated less binding affinity towards the EGFR binding site only with a hydrophobic
interaction mode with the EGFR binding pocket. In general, this result proved the
significant activity of MMA132 more than MMA102.

4.8 Summary and Conclusion
In summary, MRP2 has been highly expressed in resistance HepG2 cell line to Erlotinib.
In contrast the sensitive HepG2 cell line, the level of MRP2 was extremally low comparing
to resistance cell line to Erlotinib. In addition, MK571 (MRP2 inhibitor) showed moderate
activity against resistant HepG2 cell (18.5 µM). Also, combination 13 µM of MMA 132
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with 15 µM of MK571 enhanced the activity of MK571 from 18.5 µM to 10 µM. On the
other hand, combination of 20 µM of MMA102 with 15 µM does not change the activity
of MK571.
In the meantime, cytotoxicity of MK571 enhanced significantly in combination
with 13 µM of MMA132. A significant increase of MK571 cytotoxicity from 18.5 µM to
10 µM. This clearly demonstrate the potential anticancer activity of MMA132 in
controlling HepG2-R to Erlotinib.
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